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EXECUTIVE SUMMARY 
 
In the Middle East and North Africa (MENA), several countries are experiencing emerging HIV 
epidemics among the most at risk populations (MARPs) of HIV infection: injecting drug users 
(IDUs), men who have sex with men (MSM), and female sex workers (FSWs). Identifying the 
key modes of HIV transmission and the populations where the largest numbers of HIV infection 
are occurring is therefore critically needed in order to prioritize prevention interventions.  
 
In this report, we use the findings of the MENA HIV/AIDS Synthesis Project, the most 
comprehensive systematic review of all available biological, behavioral, and contextual data 
about HIV/AIDS in MENA, to describe the status of the HIV epidemic in Morocco, and to 
provide the basis for the estimates of HIV incidence by modes of transmission (MoT) model 
input parameters. For the MoT analysis, we used the MoT mathematical model developed by the 
UNAIDS Reference Group on Estimates, Modelling and Projections. This model uses input data 
on the current prevalence of HIV infection, the number of individuals in particular risk groups, 
and the risk of exposure to infection within each group to estimate the contribution of different 
risk groups in the population to HIV incidence.  
 
The HIV MoT Analysis in Morocco project was sponsored and led by the Morocco Ministry of 
Health and was funded by the Joint United Nations Programme on HIV/AIDS (UNAIDS). The 
scientific study was conducted through a joint collaborative partnership between the Infectious 
Disease Epidemiology Group at the Weill Cornell Medical College in Qatar (WCMC-Q), the 
Morocco Ministry of Health and National AIDS Program, and the headquarters and Morocco 
country office of the Joint United Nations Programme on HIV/AIDS. During the implementation 
of the MoT exercise, a workshop was held in Rabat, Morocco with national stakeholders, during 
which a consensus on the values and ranges of plausibility for the parameters of the MoT model 
was reached.  
 
According to the findings of the Morocco HIV/AIDS Synthesis Review delineated below, there 
is no evidence for an HIV epidemic in the general population of Morocco, with all the evidence 
indicating that the general population is not, and unlikely will be in the foreseeable future, a 
major driver of HIV dynamics in Morocco. However, similar to what is observed in other 
MENA countries, a trend of emerging epidemics among MARPs seem to be establishing, though 
still at apparently relatively low prevalence. While the epidemiological evidence among IDUs 
and MSM remains insufficient, there are some data suggesting the possibility of concentrated 
epidemics among them. Meanwhile, there is sufficient evidence suggesting HIV transmission 
among FSWs, with a concentrated epidemic in some part of Morocco such as Sous Massa Draa. 
HIV prevalence among potentially bridging populations still appears to be limited and parenteral 
transmission beyond IDU seems to be virtually non-existent. Despite high levels of basic HIV 
knowledge, levels of comprehensive knowledge remain low with many misconceptions noted as vi 
 
well as generally negative attitudes towards people living with HIV (PLHIV). Overall, condom 
use remains limited among the various population groups in Morocco including MARPs, with 
the exception of FSWs with access to voluntary counseling and testing (VCT) services. 
 
Confirming the epidemic profile portrayed in the Morocco HIV/AIDS Synthesis Review, the 
MoT analysis has indicated that the core drivers of the HIV epidemic in Morocco are most at risk 
networks (MARNs) including commercial heterosexual sex networks, MSM networks, and IDU 
networks, which together contribute about two-thirds of the total HIV incidence (Figures A and 
B below). Commercial heterosexual sex networks are the largest of the three kinds of MARNs 
followed by MSM then IDUs. Though HIV incidence rate in the low-risk population is very 
small, the actual number of new infections among them is still considerable because this risk 
group comprises most of the sexually active population in Morocco. The MoT model also 
showed that men and women contribute nearly equally to HIV incidence in this country. 
However, the key risk factor for HIV infection among men is engagement in MARNs while the 
leading risk factor for HIV infection among women is an infected spouse. Exceedingly small 
HIV incidence is also predicted to be arising from medical injections or blood transfusions. 
Finally the model predicted that HIV prevalence may increase in the future among IDUs, MSM, 
and FSWs and their clients, while HIV prevalence in the general population is likely to remain at 
very low levels. 
 
Figure A. Distribution of new HIV infections 
by mode of exposure as predicted by the MoT 
model for Morocco. 
Figure B. Distribution of new HIV infections 
by mode of exposure including the 
uncertainty in the MoT model predictions for 
Morocco.  
   
 
 
The work hereby presented has several limitations related to the MoT model structure as well as 
to gaps in the available scientific evidence. Among the limitations inherent to the mathematical 
model used is the fact that it does not incorporate overlapping risk factors, it calculates HIV 
incidence over the short-term of only one year, it assumes an average risk behavior rather than a vii 
 
distribution of risk behaviors within each risk group, and it is applied at the national level rather 
than at a local or regional level. In addition, though Morocco is one of the leading two countries 
in MENA in terms of availability of HIV-related data, key strategic scientific data are either 
lacking or of limited quality or representativeness, thereby hindering our ability to reach 
adequately precise predictions.  
 
The MoT analysis in Morocco has highlighted the urgent need to conduct representative and 
multi-center integrated bio-behavioral surveillance surveys among MARPs incorporating state of 
the art sampling methodologies for hidden and hard-to-reach populations. It is also a priority for 
HIV research in Morocco to perform mapping and scientific risk group size estimation of IDUs, 
MSM, and FSWs and their clients for a better quantitative assessment of HIV epidemiology and 
trends. The geographic coverage of the already established sentinel surveillance system also 
needs to be expanded. Finally it is essential to conduct a population-based sexual behavior 
survey on a nationally representative sample to complement our knowledge on key indicators 
needed for a better understanding of the epidemic and a better quantification of risk behavior 
among the different relevant population groups in the country.  
 
In view of the findings of the MoT, HIV response and programming in Morocco need to focus 
on the key groups at risk of HIV infection: IDUs, MSM, and FSWs and their clients. HIV testing 
and treatment must be very aggressively expanded among these population groups and 
development of awareness programs regarding condom use is warranted. Also, with a 
geographically heterogeneous HIV transmission, HIV response must be tailored to the nature of 
HIV transmission across the different parts of the country with a priority given to risk groups and 
geographic settings where HIV is already endemic. 
 
In conclusion, the evidence gathered in this report indicated that MARNs involving FSWs and 
their clients, MSM, and IDUs predominantly drive HIV transmissions in Morocco, and that these 
are the populations for which HIV response and programming efforts must be prioritized. Most 
high-risk behaviors are practiced by men, and though about half of incident HIV infections are 
among women, the majority of women acquire their infection from their infected husbands. 
There is also very limited HIV transmission in the general population in Morocco, with most 
HIV transmissions in the general population being linked directly to transmissions originating in 
MARNs. HIV counseling, testing, and treatment coverage among the key populations at risk is 
still far below what is needed and  needs to be aggressively expanded among these population 
groups. Finally, there are still large gaps in our knowledge of the HIV epidemic in Morocco. 
Scientific research efforts must be enhanced in line with the research priorities in order to allow 
an evidenced-based, or at least evidence-informed, HIV policy.   viii 
 
ACRONYMS 
 
 
ANC  Antenatal clinics 
CS  Commercial sex 
CA  Consensus agreement in the national MoT workshop 
CRFs  Circulating recombinant forms  
DHS  Demographic and Health Survey  
FSWs  Female sex workers  
GA  Global analyses 
HCV   Hepatitis C virus  
HPV  Human Papillomavirus  
HS  Heterosexual sex 
HSV-2  Herpes simplex virus type 2  
IBBSS  Integrated bio-behavioral surveillance surveys  
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MARP  Most at risk population  
MARN  Most at risk network 
MENA  Middle-East and North Africa  
MoT  Modes of Transmission  
MSM  Men who have sex with men  
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NSP  National Strategic Plan  
PLHIV  People living with human immunodeficiency virus  
RDS  Respondent driven sampling  
RSA  Rapid Situation Assessment 
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CHAPTER I. INTRODUCTION AND METHODOLOGY 
 
1.1  INTRODUCTION 
 
Challenging the widely-held misconception that there are very little data about HIV in the 
Middle-East and North Africa (MENA), the MENA HIV/AIDS Synthesis Project,
1 a 
comprehensive review of all available biological, behavior, and contextual data about HIV in the 
MENA region, has recently provided a description of the epidemiological profile of the HIV 
epidemic in MENA. It has shown that while MENA has lower HIV potential than other regions, 
especially in the general population, trends indicate the emergence in many countries of 
concentrated epidemics among the most at risk populations (MARPs) of HIV infection, mainly 
injecting drug users (IDUs) and men who have sex with men (MSM). In most settings, the 
prevalence of HIV among female sex workers (FSWs) continues to be at relatively low levels, 
with the exception of a few countries that have witnessed concentrated epidemics among this 
MARP. In some settings though, there is some evidence for low intensity HIV endemic 
transmission among FSWs, with an HIV prevalence much higher than that in the general 
population but still lower than the 5% threshold defining epidemic concentration.
2 With the 
epidemic still at rather early stages in much of MENA countries, there is a narrowing window of 
opportunity that should not be missed to control the epidemic in the region.  
 
Though HIV prevention is best achieved by addressing the structural factors that drive risk 
behavior practices, the priority in the public health sector should be on addressing the direct 
factors that put individuals at risk of HIV exposure, since tackling structural factors takes time 
and is to a large extent beyond the control of the public health community.
3 As almost all 
infections occur when an infected individual shares body fluids with an uninfected individual, 
prevention programs must focus on addressing the situations on which this is happening,
3-4 and 
careful analysis of the patterns of transmission must be conducted to inform policy decisions. 
 
The current work in Morocco is the first Modes of Transmission (MoT) analysis in the MENA 
region. It intends to analyze the distribution of new infections by mode of exposure drawing on 
existing reviews and data collected on HIV and sexually transmitted infections (STIs). In 
Morocco, the availability of a relatively good volume of HIV data, the admirable HIV response 
efforts at the national level in comparison to other MENA countries, and the presence of a highly 
active civil society and NGOs working on HIV prevention and treatment services, have 
facilitated the MoT work in this country. By identifying the distribution of target populations and 
MARPs accounting for HIV infections, the MoT work provides a systematic basis for defining 
recommendations for national prevention strategies in Morocco.  
 2 
 
1.2  METHODOLOGY 
 
1.2.1  Conceptual framework for HIV epidemiology 
 
The risk of infection by HIV depends on the mode of transmission, HIV prevalence, and 
behavioral attributes of the population. Human populations exhibit widely variable sexual and 
injecting drug risk behaviors, a heterogeneity in risk conventionally conceptualized in terms of 
three population groupings (Figure 1).
5 The first is the core group (that is MARPs) which 
experiences the highest risk of exposure to HIV. The high-risk core population typically 
encompasses IDUs, MSM including male sex work(ers), and FSWs. The second group is the 
bridging population, such as truck drivers and clients of FSWs, which experiences an 
intermediate risk of exposure and provides links between the high-risk core group and the third 
group of low risk, which is the general population and which encompasses most of the 
population in any community.  
 
Figure 1. Heterogeneity in risk of exposure to a sexually transmitted infection in a given 
population. 
 
 
The general population also includes vulnerable populations who are generally at low risk of 
HIV infection, such as prisoners, youth, and mobile populations, but are vulnerable to practices 
that may put them at higher risk of HIV infection. Once these vulnerable populations adopt 
higher risk practices, they become part of the core or bridging populations. Different risk groups 
for different modes of HIV transmission can overlap providing opportunities for an infection in 
one risk group to seed an epidemic in another group. The size and pattern of the epidemic 
depends also on the manner of mixing between the different risk groups, HIV prevalence in the 
different risk groups, and size of the different risk groups.  
 
General Population 
(Including Vulnerable 
Populations) 
Bridging Populations  
Core Group  
(IDUs, MSM & FSWs) 3 
 
1.2.2  Morocco HIV/AIDS Synthesis Review 
   
Considerable evidence on HIV epidemiology in Morocco was recently identified through the 
MENA HIV/AIDS Epidemiology Synthesis Project.
1 In this MoT in Morocco Report, we use 
the available evidence as extracted from the MENA HIV/AIDS Synthesis Project, as well as 
further data provided by national stakeholders, to describe and draw relevant conclusions about 
the current state of the HIV epidemic in this country. Results of the synthesis are used as the 
main reference for the assumptions on the different parameters of the MoT model. 
 
The following data sources were used in the extensive MENA HIV/AIDS Synthesis Project:  
  Medline (PubMed) using a strategy with both free text and MeSH headings and with no 
language or year limitation. The following set of criteria were used as part of the 
comprehensive search of the Medline database: 
o  Studies of HIV infectious spread in its different modes of transmission under the strategy of ("HIV 
Seropositivity" OR "HIV" OR "HIV Infections") AND ("Middle East" OR "Islam" OR "Arabs" 
OR "Arab World" OR "Africa, Northern" OR "Mauritania" OR "Sudan" OR "Somalia" OR 
"Djibouti" OR "Pakistan").  
o  Studies of sexual behavior and levels of risk behavior under the strategy of ("Sexual Behavior" 
OR "Sexual Partners" OR "Sexual Abstinence" OR "Unsafe Sex" OR "Sexology" OR 
"Reproductive Behavior" OR "Safe Sex" OR "Condoms" OR "Sex") AND ("Middle East" OR 
"Islam" OR "Arabs" OR "Arab World" OR "Africa, Northern" OR "Mauritania" OR "Sudan" OR 
"Somalia" OR "Djibouti" OR "Pakistan").  
o  Studies of herpes simplex virus type 2 sero-prevalence under the strategy of ("Herpesvirus 2, 
Human" OR "Herpes Genitalis") AND ("Middle East" OR "Islam" OR "Arabs" OR "Arab World" 
OR "Africa, Northern" OR "Mauritania" OR "Sudan" OR "Somalia" OR "Djibouti" OR 
"Pakistan"). 
o  Studies of human papillomavirus and cervical cancer under the strategy of ("HPV" OR "Human 
papillomavirus" OR "Human papilloma virus" OR "Cervical cancer") AND ("Middle East" OR 
"Islam" OR "Arabs" OR "Arab World" OR "Africa, Northern" OR "Mauritania" OR "Sudan" OR 
"Somalia" OR "Djibouti" OR "Pakistan"). 
o  Studies of bacterial sexually transmitted infections under the strategy of ("Chlamydia" OR 
"Chlamydia Infections" OR "Chlamydia trachomatis" OR "Gonorrhea" OR "Neisseria 
gonorrhoeae" OR "Syphilis" OR "Vaginosis, Bacterial" OR "Pelvic Inflammatory Disease") AND 
("Middle East" OR "Arabs" OR "Islam" OR "Arab World" OR "Africa, Northern" OR 
"Mauritania" OR "Sudan" OR "Somalia" OR "Djibouti" OR "Pakistan").  
o  Studies of hepatitis C virus under the strategy of ("Hepatitis C" OR "Hepatitis C Antibodies" OR 
"Hepatitis C Antigens") AND ("Middle East" OR "Islam" OR "Iran" OR "Arabs" OR "Arab 
World" OR "Africa, Northern" OR "Mauritania" OR "Sudan" OR "Somalia" OR "Djibouti" OR 
"Pakistan"). 
  Peer-reviewed publications published in local and regional research journals not indexed 
in Medline (PubMed), but identified most often through the use of Google Scholar.  
  Country-level reports, governmental studies and publications, and other institutional 
reports related to HIV. 
  International organizations reports and databases. 
  Demographic and Health Survey (DHS) reports. 4 
 
  The WHO/EMRO database of notified HIV/AIDS cases and surveillance reports. 
   Consultations with key experts, public health officials, researchers, and academics in the 
region and beyond.   
 
1.2.3  MoT model 
 
1.2.3.1 Model structure 
 
We used the MoT model to estimate the expected short term incidence of HIV infections among 
the adult population stratified by mode of transmission.
6-7 The model was developed by the 
UNAIDS Reference Group on Estimates, Modelling and Projections and uses input data on the 
current prevalence of HIV infection, the number of individuals in particular risk groups, and the 
risk of exposure to infection within each group to estimate the contribution of different risk 
groups in the population to HIV incidence. The model assumes the binomial function in terms of 
the number of partners and number of contacts with each partner to estimate the risk of infection 
in a susceptible individual in any particular risk group. Details of model structure and 
instructions for application can be found at 
http://www.unaids.org/en/KnowledgeCentre/HIVData/Epidemiology/EPI_software2009.asp.
7  
 
1.2.3.2 Definitions of risk groups 
 
Table 1 describes the definition used in the MoT model and in this report to classify individuals 
according to risk behavior. 
 
Table 1. Definitions used in the model to classify individuals according to risk behavior. 
Risk group  Definition 
Most at risk population (MARP)  Individuals who are IDUs, MSM, or FSWs 
Most at risk network (MARN)  Individuals who engage in a risk network of  IDUs, MSM, or 
FSWs and their clients  
Individuals engaging in casual HS (intermediate risk group)  Individuals who have had more than one sexual partner in 
the last year 
Partners of IDUs, partners of clients of FSWs, female 
partners of MSM, partners of individuals engaging in casual 
HS 
Individuals who have had one sexual partner in the last year, 
and whose partners are allocated to the IDUs, clients of 
FSWs, MSM or casual HS risk groups 
Individuals engaging in low-risk HS  Individuals who have had one heterosexual sex partner in the 
last year and their partners have also had only one 
heterosexual sex partner in the last year. This group consists 
of individuals in monogamous partnerships who are not only 
faithful to their partners, but their partners are faithful to 
them, and their partners are neither IDUs nor MSM 
Individuals at no risk  Individuals who have had no sexual partners in the last year. 
This may be a result of primary abstinence (never had sexual 
intercourse) or secondary abstinence (had sexual intercourse 
in the past, but are not sexually active currently). 
FSWs: Female sex workers, HS: heterosexual sex, IDUs: Injecting drug users, MSM: Men who have sex with men 
 5 
 
1.2.3.3 Uncertainty analysis 
 
Due to data limitations, there are uncertainties in the values of the model parameters. The 
uncertainty can arise from lack of studies measuring specific input parameters, limitations in the 
quality of studies used to provide input data, variation in estimates between studies, and variation 
in power, representativeness, and generalizability of study estimates. Therefore, we conducted an 
uncertainty analysis to assess the reliability of, and uncertainty around, our calculated estimates 
by using the uncertainty module of the MoT model that was developed by John Stover from the 
Futures Institute.
8 
 
This module allows the user-specified model parameters to vary simultaneously and randomly 
within a range of uncertainty for specified number of model runs. Each run yields different 
estimates of the annual numbers of incident cases per risk group and of the total annual incidence 
based on the selected set of values of the model parameters. The range of plausibility for the total 
annual incidence was determined by the range obtained from the UNAIDS SPECTRUM model
9 
for Morocco.
10 The median of all selected plausible outputs is then calculated and the uncertainty 
is described by plausibility bounds defined as the 2.5 and 97.5 percentiles. 
 
1.2.3.4 MoT model process 
 
The MoT in Morocco Report was prepared by the Infectious Disease Epidemiology Group at the 
Weill Cornell Medical College in Qatar (WCMC-Q), in collaboration with the Ministry of Health 
and National Aids Program in Morocco, and the UNAIDS headquarters and Morocco country 
office. The MoT model process in Morocco started by building direct contacts with the 
Epidemiology and Analysis Division at UNAIDS Headquarters, UNAIDS country-level office in 
Morocco, and National AIDS program in Morocco. Through these contacts, a preliminary work 
plan was formed and a timetable for the conduct of the project and MoT workshop was agreed. A 
systematic review of all HIV-related data in Morocco was then conducted based on the MENA 
HIV/AIDS Synthesis Project.
1, 11 Further data needed not available through the MENA 
HIV/AIDS Synthesis Project were requested from the country-level partners and subsequently 
incorporated in the Morocco HIV/AIDS Synthesis Review. 
 
We conducted the MoT workshop and field visit in Morocco in the week of April 26, 2010 to 
meet with HIV/AIDS stakeholders including, but not limited to, National AIDS Program, 
regional team officers working on HIV at the Ministry of Health, Sentinel Surveillance Team, 
National Institute of Hygiene (National Laboratories), Blood Bank, UNAIDS country-level 
office, NGOs working with key populations at risk, academics, and other persons engaged in 
HIV efforts in Morocco. 
 6 
 
The primary goal of the workshop was to arrive at a consensus for the values and ranges of 
plausibility for the parameters of the MoT model. Additional aims of the workshop were 
introduction and overview of the MoT model and MoT model process, overview of HIV 
epidemiology in MENA through the findings of the MENA HIV/AIDS Synthesis Project, 
discussion of HIV/AIDS synthesized data for Morocco, identification and inclusion of data not 
yet included in the HIV/AIDS data synthesis, discussion of the quality of available HIV/AIDS 
data, providing a firsthand experience in using the MoT model, discussion and validation of the 
model results, formulation of recommendations based on model findings, identification of gaps 
in HIV data and opportunities to address these gaps, formulation of a work plan and factoring in 
findings of the MoT model in other HIV efforts in Morocco, and discussing an outline for the 
MoT report describing the process and findings of the MoT project.  
 
Following the workshop and field visit, the Morocco MoT report was drafted and submitted for 
review to national partners, UNAIDS country-level office, and UNAIDS headquarters. 
Suggestions and recommendations were incorporated in a revised version of the report. The 
findings of the model were then presented at the National Strategic Plan (NSP) Review Meeting 
and its results were incorporated in the formulation of the NSP. The findings of the project were 
also factored in the Morocco third-round application for the Global Fund. Dissemination of the 
final findings of the model was conducted through a national workshop in October, 2010. The 
final version of the model was submitted to national partners, UNAIDS country-level office, and 
UNAIDS headquarters to be used for the next iterations and updates of this model in subsequent 
years. 
 7 
 
CHAPTER II. REVIEW OF HIV EPIDEMIOLOGY IN MOROCCO 
 
The estimated number of adults (15-49 years) living with human immunodeficiency virus 
(PLHIV) in 2009 in Morocco, using the SPECTRUM model,
9 is 22,500 with a range between 
18,630 and 28,555.
10, 12 Using the EPP mode,l
9 the estimate for 2010 is 25,000 adults older than 
15 years of age with a range of 19,000 to 33,000.
13 In this chapter, we describe the nature of HIV 
epidemiology among the epidemiologically relevant population groups in Morocco: FSWs, 
MSM, IDUs, potential bridging populations, and the general population. We also describe 
HIV/AIDS vulnerability settings and provide some further evidence related to HIV epidemiology 
in Morocco, as well as describe HIV/AIDS knowledge and attitudes. 
 
 
2.1  Commercial heterosexual sex networks and HIV 
 
Data on the prevalence of women engaging in sex work in Morocco are scarce. In one available 
study among hospital attendees in Morocco, 0.5% reported ever practicing sex work.
14 Table 2 
describes HIV point prevalence rates among FSWs and other MARPs in Morocco. It summarizes 
data from available studies as well as data abstracted from the US census bureau database.
15  
According to the available data, HIV prevalence among FSWs ranged between 0
16 and 7.14%.
15 
Table 3 indicates a higher prevalence of HIV among FSWs in Sous Massa Draa compared to the 
national prevalence suggesting more active HIV dynamics among FSWs in this region.
17  
 
FSWs and risk behavior 
 
In one study of 786 FSWs from urban settings in Morocco, slightly over 50% had one client 
during the last working day, 18% had two clients and 33.3% had less than one client.
18 The 
average number of clients during the last seven days was around 4.3 clients.
18 In parallel, 20.8% 
reported having one non-paying sexual partner while 5.1% had multiple such partners.
18 The 
prevalence of IDU among this sample of FSWs ranged between 0.7 and 1.1%.
18 In another study 
of 141 FSWs in Morocco, 70% of the respondents had more than 4 clients per week.
19 
 
 
 
 8 
 
Table 2. HIV prevalence among different most at risk populations in Morocco. 
Population  Source  Year  Sample Size  Prev. HIV1  Prev. HIV2  Comments 
FSWs             
  US Census Bureau,
15  1984-7  27  3.7%    Casablanca 
  US Census Bureau,
15  1989  28  7.14%    Casablanca 
  US Census Bureau,
15  1989  28    0.0%  Casablanca 
  US Census Bureau,
15  2001  217  2.3%     
  WHO/EMRO Database,
20      1.4%     
  Ministry of health, 2010
16  2001  217  2.30%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2002  350  3.14%    Sentinel surveillance, Incarcerated 
  US Census Bureau,
15  2003  264  2.27%    Sentinel surveillance 
  Khattabi 05,
21  2003    2.52%    Sentinel surveillance, STI clinics 
  Ministry of health, 2010
16  2003  148  2.03%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2003  116  2.59%    Sentinel surveillance, Medical centers 
  Ministry of health, 2010
16  2003  264  2.27%    Sentinel surveillance, Total FSWs 
  Ministry of health, 2010
16  2004  332  0.90%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2004  272  4.41%    Sentinel surveillance, Medical centers 
  Ministry of health, 2010
16  2004  167  0.00%    Sentinel surveillance, STI clinics 
  Ministry of health, 2010
16  2004  771  1.95%    Sentinel surveillance, Total FSWs 
  Ministry of health, 2010
16  2005  90  3.33%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2005  125  1.60%    Sentinel surveillance, Medical centers 
  Ministry of health, 2010
16  2005  215  2.33%    Sentinel surveillance, Total FSWs 
  Ministry of health, 2010
16  2006  228  0.00%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2006  303  0.33%    Sentinel surveillance, Medical centers 
  Ministry of health, 2010
16  2006  119  0.00%    Sentinel surveillance, STI clinics 
  Ministry of health, 2010
16  2006  650  0.15%    Sentinel surveillance, Total FSWs 
  Ministry of health, 2010
16  2007  178  3.37%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2007  476  2.73%    Sentinel surveillance, Medical centers 
  Ministry of health, 2010
16  2007  156  1.28%    Sentinel surveillance, STI clinics 
  Ministry of health, 2010
16  2007  810  2.59%    Sentinel surveillance, Total FSWs 
  Ministry of health, 2008
19  2007  141  1.5%    STD clinics, Agadir, Rabat, Salé & Tanger 
  Ministry of health, 2010
16  2008  126  3.97%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2008  712  1.83%    Sentinel surveillance, Medical centers 
  Ministry of health, 2010
16  2008  241  2.07%    Sentinel surveillance, STI clinics 
  Ministry of health, 2010
16  2008  1,079  2.13%    Sentinel surveillance, Total FSWs 
  Ministry of health, 2010
16  2009  151  3.97%    Sentinel surveillance, Incarcerated 
  Ministry of health, 2010
16  2009  367  4.09%    Sentinel surveillance, Medical centers 
  Ministry of health, 2010
16  2009  447  0.45%    Sentinel surveillance, STI clinics 
  Ministry of health, 2010
16  2009  965  2.38%    Sentinel surveillance, Total FSWs 
  Ministry of health, 2010
16  2008  3,461  1.2%    VCT attendees 9 
 
Table 2 continued. HIV prevalence among different most at risk populations in Morocco. 
Population  Source  Year  Sample Size  Prev. HIV1  Prev. HIV2  Comments 
  Ministry of health, 2010
16  2009  5,024  1.5%    VCT attendees 
MSM             
  US Census Bureau,
15  1984-7  52  3.85%    Casablanca 
  WHO/EMRO Database,
20  1989  55  10.9%     
  Ministry of health, 2010
16  2008  89  4.49%    Sentinel surveillance  
  Ministry of health, 2010
16  2008  1,147  1.2%    VCT attendees 
  Ministry of health, 2010
16  2009  1,216  2.2%    VCT attendees 
  Ministry of health, 2010
16  2009  39  0.0%    Sentinel surveillance  
IDUs             
  Ministry of health, 2010
16  2005  133  0.0%    Sentinel surveillance  
  Ministry of health, 2010
16  2006  147  0.0%    Sentinel surveillance  
  Mathers 08,
22  2006    6.5%    Data from registration/case notification  
  Ministry of health, 2010
16  2007  30  0.0%    Sentinel surveillance  
  Ministry of health, 2010
16  2008  61  1.6%    Sentinel surveillance  
  Ministry of health, 2010
16  2008  77  1.3%    VCT attendees 
  Ministry of health, 2010
17  2008    0.0%    RSA, Al-Hoceima 
  Ministry of health, 2010
16  2009  16  6.3%    VCT attendees 
  Ministry of health, 2010
16  2009  66  0.0%    Sentinel surveillance 
NIDUs             
  Ministry of health, 2010
16  2008  95  0.0%    Sentinel surveillance 
  Ministry of health, 2010
16  2009  146  2.05%    Sentinel surveillance 
Suspected HIV persons & those reporting risky behavior         
  US Census Bureau,
15  1991-8    5.5%    National Center of Diagnosis.  
  US Census Bureau,
15  1991-9  12,981  5.05%    National Center of Diagnosis. 
  US Census Bureau,
15  1999    8.0%    National Center of Diagnosis.  
FSWs: Female sex workers, IDUs: Injecting drug users, MSM: Men who have sex with men, NIDUs: Non-injecting drug users, RSA: Rapid Situation Assessment, STD: Sexually 
transmitted disease, STIs: Sexually transmitted infections, VCT: Voluntary HIV counseling and testing 
 
 
Table 3. Prevalence of HIV among FSWs in Morocco, national versus Sous Massa Draa, HIV sentinel surveillance, 2001-9.
17 
  2001  2002  2003  2004  2005  2006  2007  2008  2009 
National  2.30  3.14  2.27  1.95  2.20  0.15  2.71  2.13  2.38 
Sous Massa Draa   5.26  5.06  3.60  6.28  3.18  4.26  5.34  5.73  8.14 10 
 
2.2  Men Who Have Sex with Men and HIV 
 
Data on the prevalence and risk behavior of MSM are limited in Morocco. As can be seen in 
Table 2, HIV prevalence among MSM in Morocco ranged between 0
16 and 10.9%.
20 In the study 
of mainly IDUs, 13.1% of males reported having same-sex sexual relations,
23 while in another 
study among youth in Morocco, 3.7% of males between ages 15 and 24 reported ever having 
anal sex with a male.
24 Nearly 9% of a group of truck drivers reported having a same-sex sexual 
partner during the last year.
25 
 
 
2.3  Injecting Drug Users and HIV 
 
2.3.1  HIV prevalence 
 
Injecting drug use is one of the leading modes of HIV transmission and accounts for about 10% 
of HIV/AIDS cases worldwide.
26 In Morocco, IDU has contributed somewhat considerably to 
the HIV epidemic.
26-27 HIV point-prevalence measures among IDUs in Morocco can be found in 
Table 2.
15 The prevalence of HIV ranged between 0.0
28 and 6.3%
16 among different IDU 
population samples.   
 
2.3.2  Prevalence of drug injection 
 
The estimated number of IDUs in Morocco is 18,500 and the IDU prevalence is 0.1%.
29 In a 
sample of drug users with  74% of  IDUs, 15.6% were females, and 10.4% of the strictly IDUs 
were females.
23 In that study, 75% of the male drug users were IDUs versus 49.4% of the female 
drug users.
23 Also, 60% of all IDUs were unepmployed.
23 
 
2.3.3  IDUs and risk behavior 
 
2.3.3.1 Sharing of injecting equipment among IDUs 
 
The key risk behavior exposing IDUs to HIV infection is sharing of injecting equipment. In one 
study, it was reported that 63.9% of IDUs shared syringes.
23 However, 76.9% of them would 
disinfect a shared syringe each time before use, although only 16% of those would use proper 
means to do so while the rest would only use water.
23  
 
2.3.3.2 Engagement of IDUs in sexual risk behavior 
 
Studies show that IDUs in Morocco engage in high risk sexual behavior as 47.6% of males and 
70.1% of females of a group of mainly IDUs reported multiple sexual partners in the last 12 11 
 
months.
23 In this study, 13.1% of males reported having same-sex sexual relations,
23 while 64.6 
and 74.0% of male and female participants, respectively, reported selling or paying for sex.
23  
 
 
2.4  Potential Bridging Populations and HIV 
 
Data on HIV point-prevalence surveys among potential bridging populations are still limited in 
Morocco. Available data among several potential bridging population groups are summarized in 
Table 4. They suggest low HIV prevalence reaching a maximum of 1.01% among truck drivers 
according to sentinel surveillance data in 2005. Still, similar data for the subsequent years 
indicates zero HIV prevalence among truck drivers.  
 
Table 4. HIV prevalence among potential bridging populations in Morocco. 
Population  Source  Year  Sample Size  Prev.  HIV-1  Comments 
Seamen           
 
16  2004  544  0.0%  Sentinel surveillance  
 
16  2005  356  0.28%  Sentinel surveillance  
 
16  2006  483  0.62%  Sentinel surveillance  
 
16  2007  1,370  0.29%  Sentinel surveillance  
 
16  2008  730  0.14%  Sentinel surveillance  
 
16  2009  161  0.0%  Sentinel surveillance  
Truck drivers           
 
16  2005  199  1.01%  Sentinel surveillance  
 
16  2006  412  0.0%  Sentinel surveillance  
 
16  2008  276  0.0%  Sentinel surveillance  
 
16  2009  93  0.0%  Sentinel surveillance  
Military personnel           
 
15  1993?  24,800  0.07%  Males 
 
 
Bridging populations and risk behavior 
 
One cross sectional study was conducted in 2007 among truck drivers in Morocco describing the 
characteristics of this population and their knowledge, attitudes, and behavior towards STIs and 
HIV/AIDS.
25 Among the 484 truck drivers interviewed, 48.6% spent on average more than 3 
consecutive nights away from their residence and 45.8% were currently married. About 32% of 
the respondents were neither married nor in a stable sexual partnership.
25 Among the total 
sample, 1.3% and 22.6% reported injecting and non-injecting drug use respectively. The vast 
majority of the truck drivers (90.5%) ever had sex and the average age at sexual debut was 17 
years.
25  
 
In the last year, 80.9% of the truck drivers in that study had any type of sexual relation. Table 5 
summarizes the details of the sexual activity of those respondents. It indicates a high level of 
sexual activity characterized by large numbers of partners of different types, with particularly 
substantial contact with FSWs. On average, truck drivers had 3 coital acts with FSWs in the last 
month. It was also noted that 25% of truck drivers had more than 24 FSW partners per year, 
more than 2 casual heterosexual partners per year, or more than 7 same-sex partners per year.
25  12 
 
Almost one fourth of truck drivers reported having urethral discharge in the last year, and only 
13.5% have ever taken a voluntary HIV test.  
 
Table 5. Partnership description of sexually active truck drivers during the last year, Morocco.
25 
Type of sexual partner  Prevalence
* 
Number of partners in the last year 
Average  Median 
Regular partner/spouse    3  1 
Commercial partner (FSW)  78.1%  16  9 
Casual heterosexual partner  41.5%  5  3 
Same-sex partner   8.7%  5  5 
* Fraction of truck drivers having sex in the last year with this type of sexual partner 
FSW: Female sex workers 
 
 
2.5  General Population and HIV 
 
HIV prevalence has been measured in a number of general population groups in Morocco. Data 
indicate that the prevalence rate is very low and that there is very limited HIV transmission 
within the general population (Table 6). 
 
Table 6. HIV prevalence among different general population groups in Morocco.  
Population  Source   Year   Sample  
Size  HIV-1   HIV-2 Comments 
Blood donors           
 
15  1984-7  3,577  0.03%    Casablanca 
 
15  1984-7  115    0.0%  Casablanca 
 
15  1988-93  235,000  0.01%    Casablanca 
 
15  1988  39,443  0.02%    Rabat & Casablanca.  
 
15  1989  104,359  0.02%    Rabat & Casablanca.  
 
15  1990  118,387  0.01%    Rabat & Casablanca.  
 
15  1991  207  0.0%    Casablanca 
 
15  1991  167  0.0%    Marrakech 
 
15  1991  152  0.0%    Tangier 
 
15  1991  117,191  0.01%    Rabat & Casablanca.  
 
15  1992  130,262  0.03%    Rabat & Casablanca.  
 
15  1993  125,324  0.03%    Rabat & Casablanca.  
 
15  1993  13,730  0.0%    Rabat.  
 
15  1994  114,277  0.02%    Rabat & Casablanca.  
 
15  1995  137,188  0.01%    Rabat & Casablanca.  
 
15  1996  139,234  0.01%    National  
 
15  1997  140,149  0.02%    National 
 
15  1997?  1,000  0.0%     
 
15  1998  75,379  0.01%     
 
15  1999?  1,000  0.0%    Casablanca 
 
30  2007  176,968  0.038%    National 
 
30  2007  40,813  0.016%    Rabat 
 
30  2008  190,504  0.024%    National 
 
30  2008  52,279  0.028%    Casablanca  
 
30  2008  41,578  0.02%    Rabat 
 
30  2009  202,769  0.023%    National 
 
30  2009  55,491  0.039%    Casablanca  
 
30  2009  44,136  0.011%    Rabat 
 
31-32      0.02%     13 
 
Table 6 continued. HIV prevalence among different general population groups in Morocco.  
Population  Source   Year   Sample  
Size  HIV-1   HIV-2 Comments 
Laborers              
 
33  2005    0.0%    Male  
 
21  2004    5.26%    Male  
 
16  2004  311  0.32%    Sentinel surveillance, seasonal female laborers 
 
16  2005  138  0.72%    Sentinel surveillance, seasonal female laborers 
 
16   2006  398  0.75%    Sentinel surveillance, seasonal female laborers 
 
16  2007  274  3.28%    Sentinel surveillance, seasonal female laborers 
 
16  2008  480  1.04%    Sentinel surveillance, seasonal female laborers 
 
16  2009  483  1.04%    Sentinel surveillance, seasonal female laborers 
 
16  2008  1,251  1.4%    VCT attendees  
 
16  2009  394  2.0%    VCT attendees  
Migrants              
 
16  2008  821  1.0%    VCT attendees  
 
16  2009  641  4.2%    VCT attendees  
Newly recruited employees         
 
16  1999  398  0.25%    Sentinel surveillance 
 
16  2004  705  0.0%    Sentinel surveillance 
 
16  2005  746  0.0%    Sentinel surveillance 
 
16  2006  537  0.0%    Sentinel surveillance 
People seeking health insurance card       
 
16  1999  196  0.51%    Sentinel surveillance 
 
16  2004  56  0.0%    Sentinel surveillance 
 
16  2005  526  0.0%    Sentinel surveillance 
 
16  2006  396  0.0%    Sentinel surveillance 
Pregnant women & ANC attendees       
 
15  1984-7  778  0.0%    Casablanca 
 
15  1990  363  0.0%    Casablanca 
 
15  1990?  1,043  0.0%  0.0%  Casablanca 
 
15  1991  288  0.0%    Agadir 
 
15  1991  99  0.0%    Casablanca 
 
15  1991  310  0.0%    Marrakech 
 
15  1991  131  0.0%    Tangier 
 
15  1991?  300  0.0%  0.0%   Casablanca 
 
15  1993    0.02%    National. Sentinel surveillance.  
 
15  1993?  671  0.15%    Rabat 
 
34a  1994    0.0%       
 
15  1994  447  0.0%  0.0%  Agadir, sentinel site.  
 
15  1994  207  0.0%  0.0%  Casablanca, sentinel site.  
 
15  1994  532  0.0%  0.0%  Marrakech, sentinel site.  
 
15  1994  1,245  0.0%  0.0%  Rabat, sentinel site.  
 
16  1994  3,296  0.03%    Sentinel surveillance 
 
15  1994    0.03%    National. Sentinel surveillance 
 
15  1994  865  0.11%  0.0%  Tangier, sentinel site.  
 
35  1994    0.02%     
 
34a  1996    0.0%       
 
15  1996  348  0.0%  0.0%  Casablanca, sentinel site.  
 
15  1996  1,527  0.0%  0.0%  Fes, sentinel site.  
 
15  1996  716  0.0%  0.0%  Marrakech, sentinel site.  
 
15  1996  340  0.0%  0.0%  Maknes, sentinel site.  
 
15  1996  1,256  0.0%  0.0%  Rabat, sentinel site.  
 
15  1996  719  0.0%  0.0%  Safi, sentinel site.  
 
15  1996  688  0.0%  0.0%  Tangier, sentinel site.  14 
 
Table 6 continued. HIV prevalence among different general population groups in Morocco.  
Population  Source   Year   Sample  
Size  HIV-1   HIV-2 Comments 
 
15  1996  1,054  0.0%    Tetouan, sentinel site.  
 
15  1996  8,148  0.02%     
 
15  1996    0.03%    National. Sentinel surveillance 
 
15  1996  1,011  0.1%  0.0%  Oujda, sentinel site.  
 
15  1996  489  0.2%  0.0%  Agadir , sentinel site  
 
16  1996  8,148  0.025%    Sentinel surveillance 
 
34a  1997    0.0%       
 
15  1997  1,877  0.0%     
 
15  1997  142  0.0%    Agadir, sentinel site.  
 
15  1997      0.0%  Agadir, sentinel site.  
 
15  1997  549  0.0%    Casablanca, sentinel site.  
 
15  1997    0.0%  0.0%  Casablanca, sentinel site.  
 
15  1997  1,273  0.0%    Fes, sentinel site.  
 
15  1997  230  0.0%  0.0%  Marrakech, sentinel site.  
 
15  1997  314  0.0%    Marrakech, sentinel site.  
 
15  1997  1,057  0.0%  0.0%  Maknes, sentinel site.  
 
15  1997  587  0.0%  0.0%  Oujda, sentinel site.  
 
15  1997  719  0.0%  0.0%  Safi, sentinel site.  
 
15  1997  518  0.0%  0.0%  Tangier, sentinel site.  
 
15  1997  872  0.0%    Tetouan. , sentinel site  
 
15  1997  1054    0.0%  Tetouan, sentinel site.  
 
15  1997      0.0%  Tetouan, sentinel site.  
 
15  1997    0.01%    National, Sentinel surveillance  
 
15  1997      0.01%  Oujda, sentinel site.  
 
15  1997  1,160  0.09%  0.0%  Rabat, sentinel site.  
 
16  1997  7,097  0.014    Sentinel surveillance 
 
35  1997    0.01%     
 
15  1997?  676  0.15%     
 
35  1998    0.04%     
 
34a  1999    0.0%       
 
15  1999  2,101  0.0%  0.0%  Fes, sentinel site.  
 
15  1999  646  0.0%  0.0%  Marrakech, sentinel site.  
 
15  1999  1,607  0.0%  0.0%  Maknes, sentinel site.  
 
15  1999  1,031  0.0%  0.0%  Oujda, sentinel site.  
 
15  1999  842  0.0%    Rabat. 5 health centers. 61.5% family planning 
clients, & 38.5% pregnant women 
 
15  1999  763  0.0%  0.0%  Safi, sentinel site.  
 
15  1999  1,107  0.0%  0.0%  Tetouan, sentinel site.  
 
15  1999    0.08%    National, sentinel surveillance.  
 
34a  1999    0.1%     
 
15  1999  1,633  0.12%  0.0%  Rabat, sentinel site.  
 
15  1999  704  0.14%  0.0%  Tangier, sentinel site.  
 
15  1999  543  0.74%  0.0%  Casablanca, sentinel site.  
 
16  1999  10,135  0.07%    Sentinel sites 
 
35  1999    0.07%     
 
36  1999  323  0.0%    Rabat & Salé 
 
15  1999?  676  0.15%    Casablanca 
 
16  2000    0.15%    Sentinel surveillance 
 
16  2001  3,154  0.13%    Sentinel surveillance 
 
16  2002  16,666  0.12%    Sentinel surveillance 
 
16  2003  17,614  0.13%    Sentinel sites 
 
16  2004  18,302  0.10%    Sentinel sites 15 
 
Table 6 continued. HIV prevalence among different general population groups in Morocco.  
Population  Source   Year   Sample  
Size  HIV-1   HIV-2 Comments 
 
16  2005  17,711  0.06%    Sentinel sites 
 
16  2007  16,422  0.08%    Sentinel sites 
 
16  2009  15,290  0.17%    Sentinel sites 
Taxi drivers           
 
16  1996  408  0.0%    Sentinel surveillance 
 
15  1996    0.0%    Meknes, sentinel site. Male  
 
15  1996    0.0%    Tangier, sentinel site. Male  
 
15  1999    0.0%    Tangier, sentinel site. Male  
 
16  1999  432  0.0%    Sentinel surveillance 
 
16  2005  90  0.0%    Sentinel surveillance 
Tourism sector staff           
 
15  1990?  1,618  0.31%  0.0%  Casablanca. Hotel staff 
 
15  1997?  2,748  0.11%    Tour guides and agents 
 
16  2001  815  0.0%    Sentinel sites. Hotel staff 
 
16  2004  710  0.0%    Sentinel sites. Hotel staff 
 
16  2005  847  0.12%    Sentinel sites. Hotel staff 
 
16  2006  801  0.12%    Sentinel sites. Hotel staff 
 
16  2007  269  0.0%    Sentinel sites. Hotel staff 
 
16  2008  477  0.0%    Sentinel sites. Hotel staff 
 
16  2009  269  0.0%    Sentinel sites. Hotel staff 
Women seeking family planning services       
 
36  1999  518  0.0%    Rabat & Salé 
Various general population groups       
 
15  1984-7  1,069  0.0%    Casablanca. Hospital staff 
 
15  1999    0.25%    Tetouan, sentinel site. Pre-employment 
screening for public jobs 
 
15  1999    0.51%    Fes. People requesting testing to sell fast food 
 
20      0.0%  Women at family planning clinics  
 
37      0.0%    Traditional barbers and their customers 
 
16  2008  32083  0.7%    VCT general population attendees  
 
16  2009  34694  0.6%    VCT general population attendees  
ANC: Antenatal clinics, VCT: Voluntary counseling and testing 
a Point–prevalence surveys on different population groups as extracted from UNAIDS epidemiological facts sheets on Morocco 
over the years.
34 Some of the data reported here are gleaned from country-based case notification surveillance reports,
20 or 
provided through national-level agencies. These surveys may not be conducted using sound methodology or internationally 
accepted guidelines for HIV surveillance. There are also very limited information on the populations on which these 
measurements were made. Given these limitations, the prevalence levels may not be representative of the populations that they 
are supposed to represent.  
 
 
General Population and risk behavior 
 
Data on sexual behavior among the general population continues to be rather limited in Morocco. 
However, in line to what is observed in other settings,
1 most of the sexual risk behavior appears 
to be practiced by men rather than women. A case-control study examining the epidemiology of 
Human Papillomavirus (HPV) infection, a sexually transmitted infection (STI) causing cervical 
cancer, provided valuable data on sexual behavior among general population women who were 
in the control arm of this study.
14 Almost 20% of women reported more than one lifetime sexual 
partner with 2% reporting more than three partners.
14 Six percent reported having more than one 
partner before reaching 20 years of age, and 2% reported having non-spousal sexual 16 
 
partnerships. One woman out of 203 women reported ever practicing sex work (0.5%). The study 
also reported a mean lifetime sexual partners of 1.3, a median of 1, and a range of 1-4, and that 
the median age at first sex was 18 years. Condom use was limited and 16% of women ever used 
condoms.
14  
 
There appears to be a substantial gap in age in sexual partnerships between men and women in 
Morocco with women marrying older men. Among women who had cervical cancer and reported 
first marriage/intercourse before age 15, 57% married a husband in the 20-30 years age range 
and 19% married a husband older than 30 years of age.
14 Polygamous unions were reported by 
12% of women in Morocco, and polygamy was associated, though not with statistical 
significance, with cervical cancer.
14  
 
In one study conducted in 1999 among women seeking antenatal and family planning services in 
Rabat-Salé, the average age of sexual debut was 20.1 years, and 88.5% of women seeking 
antenatal services, and 79.5% of those seeking family planning services, had sexual relations at 
least once per week. 
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2.6  Vulnerability Settings and HIV 
 
2.6.1  Youth  
In Morocco about one-third of the population are between 15-29 years of age.
38 Most of HIV 
infections in Morocco (63%) are among single and often young persons,
38 and a significant 
portion (40%) of recorded sexually transmitted disease (STD) cases were among youth 15-29 
years.
38-39 
 
Youth in Morocco report relatively high levels of risk behavior. In a study among 2,000 youth 
between the ages of 15 and 24 years,
24 36% of males and 5.2% of females declared having had a 
vaginal intercourse ever (total for both males and females is 20.6%). Also 29.3% of males and 
1.0% of females reported ever having anal sex (total 15.2%), and as much as 3.7% of males 
reported ever having anal sex with a male. The average age at first sexual act was 16.7 years for 
males and 18.2 years for females. Among the sexually active participants, 6.9% of males and 
11.3% of females declared having sexual acts regularly since puberty, 89.2% of males and 49.3% 
of females sometimes or from time to time, and 3.9% of males and 23.9% of females very rarely. 
Also, since sexual debut, 68% of males and 38.5% of females had more than one sexual partner 
(total 34.6%).
24 
  
In this same study,
24 67% of sexually active male youth declared ever having sex with a FSW 
(3.8% visit FSWs regularly and 63.4% sometimes or from time to time). During the last sex with 
a FSW, 65.3% of the youth used a condom. Overall during last sex, 71% of males and 62.5% of 
females used condoms (total 70.4%). During the last month, males used on average 1.5 condoms 
and females 2.0 condoms (total 1.5 condoms). On the other hand, 16.4% of males and 1.8% of 
females declared current use of any type of drugs.  
 
2.6.2  Prisoners  
 17 
 
Imprisonment in Morocco is rather high at 174 per 100,000 persons.
40-41 In the study of mainly 
IDUs, 45.9% had a history of incarceration for drug use.
23 Among those, 19.8% used to inject 
drugs while in prison.
23 Prisoners report higher levels of risk behavior than the rest of the general 
population even prior to incarceration. In Morocco, only 9% of female prisoners reported using 
condoms and the average number of lifetime sexual partners was 5.17.
42 Two percent of female 
prisoners in Morocco reported IDU.
42 Table 7 summarizes HIV prevalence rates among 
prisoners in Morocco. 
 
2.6.3  Other vulnerability settings 
 
Women constitute a vulnerable group in Morocco in the sense of being exposed to the infection 
through their infected husbands or partners who are mostly not aware of their infections.
43 (In the 
2003-4 DHS survey in Morocco, 52.3% of the women surveyed were currently married)
44 In 
Morocco, men were 1.6 times as likely as women to be infected with HIV,
45 and acquisition of 
STDs was more associated with male rather than female sexual behavior.
46 This reflects the 
reality that most risk behaviors are practiced by men rather than women in Morocco. A fraction 
of children may also be at risk. Child prostitution appears to be a growing problem in Morocco 
where in some settings street children approach tourists offering their sexual services .
47  
 
Table 7. HIV prevalence among prisoners in Morocco. 
Source   Year   Sample Size  Prev. HIV-1   Prev.  HIV-2  Comments 
15  1984-87  42    0.0%  Casablanca 
15  1984-87  1,312  0.15%    Casablanca 
15  1990-1  1,000  0.1%    Casablanca. 886 males & 114 females 
15  2001  94  0.0%    Females, sentinel surveillance 
15  2001  1,148  0.7%    Males, sentinel surveillance 
15  2003  1,687  0.83%    Sentinel surveillance  
16  2001  1,148  0.70%    Males, sentinel surveillance 
16  2001  94  0.00%    Females, sentinel surveillance 
16  2002  1,782  1.18%    Males, sentinel surveillance 
16  2002  138  0.72%    Females, sentinel surveillance 
16  2003  1,687  0.83%    Males, sentinel surveillance 
16  2003  55  0.00%    Females, sentinel surveillance 
16  2004  2,289  0.61%    Males, sentinel surveillance 
16  2004  167  1.20%    Females, sentinel surveillance 
16  2005  1,638  0.61%    Males, sentinel surveillance 
16  2005  61  0.00%    Females, sentinel surveillance 
16  2006  2,085  0.53%    Males, sentinel surveillance 
16  2006  95  2.11%    Females, sentinel surveillance 
16  2007  2,778  0.54%    Males, sentinel surveillance 
16  2007  141  1.42%    Females, sentinel surveillance 
16  2008  2,341  0.77%    Males, sentinel surveillance 
16  2008  474  0.00%    Females, sentinel surveillance 
16  2009  2,077  0.43%    Males, sentinel surveillance 
16  2009  275  0.73%    Females, sentinel surveillance 
42      2.0%    Females 
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2.7  Further Evidence Related to HIV Epidemiology in Morocco 
 
2.7.1  Facility-based surveillance data 
 
Since STD clinic and voluntary counseling and testing (VCT) attendees are more likely to 
represent people who visited these centers because of perceived risks, the level of HIV 
prevalence among these population groups hints at the risk of exposure to HIV in a part of the 
population with specific identifiable risk behaviors. Table 8 data suggest that HIV prevalence 
among STD clinic and VCT attendees in Morocco is generally low.  
 
Table 8. HIV prevalence for facility based surveillance data in Morocco. 
Population  Source   Year   Sample  
Size 
Prev.   
HIV-1 
Prev.   
HIV-2   Comments 
TB patients             
 
15  1988-1990  997  0.3%  0.0%  Casablanca. University hospital 
 
15  1988-1991  2,371  0.13%    Casablanca & Marrakech 
 
15  1990-1993  882  0.23%    Casablanca 
 
15  1993  1,070  0.19%    Sentinel sites 
 
15  1993  57  3.51%    Agadir 
 
15  1994  16  0.0%     
 
15  1995  847  0.12%     
 
34a  1996    0.0%     
 
34a  1996    0.0%     
 
15  1996  100  0.0%  0.0%  Casablanca. Sentinel surveillance 
 
15  1996  87  0.0%  0.0%  Fes. Sentinel surveillance 
 
15  1996  189  0.0%  0.0%  Meknes. Sentinel surveillance 
 
15  1996  314  0.0%  0.0%  Rabat. Sentinel surveillance 
 
15  1996  114  0.0%  0.0%  Tetouan. Sentinel surveillance 
 
15  1996  804  0.12%     
 
15  1996?  857  0.12%    Hospitalized in 27 provincial hospitals 
 
34a  1997    0.0%     
 
34a  1997    0.0%     
 
15  1997  60  0.0%  0.0%  Casablanca. Sentinel surveillance 
 
15  1997  39  0.0%  0.0%  Fes. Sentinel surveillance 
 
15  1997  256  0.0%  0.0%  Meknes. Sentinel surveillance 
 
15  1997  284  0.0%  0.0%  Rabat. Sentinel surveillance 
 
15  1997  72  0.0%  0.0%  Safi. Sentinel surveillance 
 
15  1997  163  0.0%  0.0%  Tetouan. Sentinel surveillance 
 
15  1997  225  0.44%     
 
15  1999  79  0.0%  0.0%  Fes. Sentinel surveillance 
 
15  1999  27  0.0%  0.0%  Meknes. Sentinel surveillance 
 
15  1999  246  0.0%  0.0%  Rabat. Sentinel surveillance 
 
15  1999  24  0.0%  0.0%  Safi. Sentinel surveillance 
 
15  1999  35    0.0%  Oujda. Sentinel surveillance 
 
34a  1999    0.6%     
 
15  1999  138  0.72%  0.0%  Tangier. Sentinel surveillance 
 
15  1999  169  1.18%  0.0%  Tetouan. Sentinel surveillance 
 
34a  1999    2.0%     
 
15  1999  62  3.221%  0.0%  Merrakech. Sentinel surveillance 
 
15  1999  72  4.17%  0.0%  Casablanca. Sentinel surveillance 
 
16  1995  857  0.12%    Sentinel surveillance 
 
16  1996  754  0.13%    Sentinel surveillance 
 
16  1997  874  0.00%    Sentinel surveillance 19 
 
Table 8 continued. HIV prevalence for facility based surveillance data in Morocco. 
Population  Source   Year   Sample  
Size 
Prev.   
HIV-1 
Prev.   
HIV-2   Comments 
 
16  1999  852  0.94%    Sentinel surveillance 
 
21  2000    0.14%    Sentinel surveillance 
 
16  2002  1,408  0.50%    Sentinel surveillance 
 
16  2003  1,070  0.19%    Sentinel surveillance 
 
16  2004  1,164  0.34%    Sentinel surveillance 
 
48  2004    1.6%     
 
16  2005  1,026  0.39%    Sentinel surveillance 
 
16  2006  1,048  0.76%    Sentinel surveillance 
 
16  2007  1,256  0.40%    Sentinel surveillance 
 
16  2008  1,191  0.42%    Sentinel surveillance 
 
16  2008  1,348  0.37    Sentinel surveillance 
STI clinic attendees            
 
15  1984-1987  82    0.0%  Casablanca 
 
15  1984-1987  261  0.0%    Casablanca 
 
15  1987-1993  2,361  0.04%    Casablanca 
 
15  1987-1993  306  0.33%    Marrakech 
 
15  1987-1993  810  0.62%    Agadir 
 
15  1989  443  0.0%  0.0%  Casablanca. 
 
15  1990  276  0.72%    Agadir 
 
15  1991  100  0.0%  0.0%  Casablanca. 
 
15  1991  317  0.0%     
 
15  1991  98  0.0%     
 
15  1991  580  0.17%    HIV1 &/or HIV2  
 
15  1991  306  0.33%    Marrakech 
 
15  1991  259  1.16%    Agadir 
 
15  1991-1993  1,322  0.0%    636 males & 686 females. 25-35Yo 
 
15  1991-1997  3,000  0.3%     
 
15  1992-1996  1,133  0.35%    Casablanca. Pasteur Institute of 
Morocco. Females 
 
15  1992-1996  1,131  0.88%    Casablanca. Pasteur Institute of 
Morocco. Males 
 
15  1992-1996  2,264  0.62%    Casablanca. Pasteur Institute of 
Morocco.Total 
 
15  1993  125  0.0%  0.0%  Casablanca. Sentinel surveillance 
 
15  1993  294  0.0%  0.0%  Marrakech. Sentinel surveillance 
 
34a  1993    0.0%     
 
15  1993  197  0.0%  0.0%  Rabat. Sentinel surveillance 
 
15  1993  1,303  0.15     
 
15  1993  404  0.25%  0.0%  Agadir. Sentinel surveillance 
 
15  1993  283  0.35%  0.0%  Tangier. Sentinel surveillance 
 
16  1993  1303  0.15%    Sentinel surveillance 
 
34a  1994    0.0%     
 
15  1994  201  0.0%  0.0%  Agadir. Sentinel surveillance 
 
15  1994  169  0.0%  0.0%  Casablanca. Sentinel surveillance 
 
15  1994  231  0.0%  0.0%  Marrakech. Sentinel surveillance 
 
15  1994  137  0.0%  0.0%  Tangier. Sentinel surveillance 
 
15  1994  1,191  0.08%     
 
15  1994  453  0.22%  0.0%  Rabat. Sentinel surveillance 
 
16  1994  1191  0.08%    Sentinel surveillance 
 
34a  1996    0.0%     
 
34a  1996    0.0%     
 
15  1996  132  0.0%  0.0%  Casablanca. Sentinel surveillance 20 
 
Table 8 continued. HIV prevalence for facility based surveillance data in Morocco. 
Population  Source   Year   Sample  
Size 
Prev.   
HIV-1 
Prev.   
HIV-2   Comments 
 
15  1996  366  0.0%  0.0%  Meknes. Sentinel surveillance 
 
15  1996  146  0.0%  0.0%  Fes. Sentinel surveillance 
 
15  1996  160  0.0%  0.0%  Oujda. Sentinel surveillance 
 
15  1996  385  0.0%  0.0%  Rabat. Sentinel surveillance 
 
15  1996  393  0.0%  0.0%  Safi. Sentinel surveillance 
 
15  1996  369  0.0%  0.0%  Tangier. Sentinel surveillance 
 
15  1996  525  0.0%  0.0%  Tetouan. Sentinel surveillance 
 
15  1996  2,844  0.11%     
 
15  1996  267  0.75%  0.0%  Agadir. Sentinel surveillance 
 
15  1996  101  0.99%  0.0%  Marrakech. Sentinel surveillance 
 
16  1996  2844  0.11%    Sentinel surveillance 
 
15  1996?  1,388  0.0%    Three cities. Sentinel surveillance 
Females 
 
15  1996?  223  1.35%    Three cities. Sentinel surveillance Males 
 
15  1996?  1,461  0.21%    Three cities. Sentinel surveillance 
 
15  1997  263  0.0%  0.0%  Fes. Sentinel surveillance 
 
15  1997  990  0.0%  0.0%  Meknes. Sentinel surveillance 
 
15  1997  1,676  0.0%    Sentinel sites 
 
34a  1997    0.0%     
 
15  1997  532  0.0%  0.0%  Safi. Sentinel surveillance 
 
15  1997  425  0.23%  0.0%  Rabat. Sentinel surveillance 
 
15  1997  282  0.35%  0.0%  Tangier. Sentinel surveillance 
 
15  1997  300  0.67%  0.0%  Tetouan. Sentinel surveillance 
 
15  1997  135  0.74  0.0%  Oujda. Sentinel surveillance 
 
15  1997  113  0.88%  0.0%  Casablanca. Sentinel surveillance 
 
34a  1997    0.9%       
 
15  1997  104  0.96%  0.0%  Agadir. Sentinel surveillance 
 
15  1997  62  1.62%  0.0%  Marrakech. Sentinel surveillance 
 
16  1997  3206  0.25%    Sentinel surveillance 
 
34a  1999    0.0%     
 
15  1999  253  0.0%  0.0%  Fes. Sentinel surveillance 
 
15  1999  550  0.0%  0.0%  Meknes. Sentinel surveillance 
 
15  1999  207  0.0%  0.0%  Oujda. Sentinel surveillance 
 
15  1999  829  0.12%  0.0%  Rabat. Sentinel surveillance 
 
15  1999  785  0.25%  0.0%  Marrakech. Sentinel surveillance 
 
15  1999  776  0.26%  0.0%  Tetouan Sentinel surveillance 
 
34a  1999    0.4%     
 
15  1999  503  0.4%  0.0%  Safi. Sentinel surveillance 
 
15  1999  431  0.46%  0.0%  Tangier. Sentinel surveillance 
 
15  1999  149  1.34%  0.0%  Casablanca. Sentinel surveillance 
 
16  1999  4483  0.25%    Sentinel surveillance 
 
15  1999?  2,088  0.6%    Casablanca. Sentinel surveillance 
 
21  2000    0.16%    Sentinel surveillance 
 
15  2001  7,405  0.09%     
 
16  2001  7402  0.09%    Sentinel surveillance 
 
15  2003  5,698  0.23%     
 
16  2003  5698  0.23%    Sentinel surveillance 
 
16  2004  7047  0.34%    Sentinel surveillance 
 
16  2005  5343  0.26%    Sentinel surveillance 
 
16  2006  8034  0.19%    Sentinel surveillance 
 
16  2007  6710  0.40%    Sentinel surveillance 
 
19  2007  986  0.2%    Agadir, Rabat, Salé and Tanger 21 
 
Table 8 continued. HIV prevalence for facility based surveillance data in Morocco. 
Population  Source   Year   Sample  
Size 
Prev.   
HIV-1 
Prev.   
HIV-2   Comments 
 
16  2008  9133  0.28%    Sentinel surveillance 
 
16  2009  7,757  0.32%    Sentinel surveillance 
 
46      2.9%     
 
49      0.62%     
 
20      0.0%    Males 
 
46      0.1%    Females 
 
20      0.2%    Females 
 
46      0.3%    Females 
 
31      5.0%    High risk and/or symptomatic attendees 
Other patients             
 
15  1984-7  303  0.0%  Casablanca. Infectious disease pts 
 
15  1984-97  22  0.0%  Casablanca. Kaposi’s sarcoma pts 
 
15  1986-97  29  6.9%  Rabat. Neurosyphilis pts. 17-70Yo 
 
15  1990?  441  0.0%  0.0% Casablanca. Venerology Dept 
 
15  1990?    0.0%   
 
15  1992  115  0.0%  Casablanca. Leprosy pts 
 
15  1993?  115  0.0%  Hospitalized pts with leprosy 
 
15  1995-6  742  0.0%  Rabat. L’Hopital militaire Mohamed V  
VCT attendees             
 
15  1988-1993  1,531  0.72%    Casablanca. Anonymous testing center 
attendees. 103 males & 355 females.  
 
15  1993  5,204  0.13%    Rabat. Anonymous testing center  
 
15  1998-1999  1,090  0.55%    Casablanca. Attending VCT clinic 
 
15  2003  1,445  2.01%    Five sites. Association du Lutte Contre 
le SIDA, free standing VCT sites 
 
15  2004  3,208  0.41%   
Mobile VCT at rural weekly markets, 
music festivals, religious pilgrimage 
sites & prostitute cruising areas 
 
15  2005  5,762  0.36%   
Mobile VCT at rural weekly markets, 
music festivals, religious pilgrimage 
sites & prostitute cruising areas 
 
15  2005  6,401  1.56%    14 VCT centers 
Various groups             
STD clinic 
attendees, pregnant 
women and patients 
with pulmonary TB  
35      0.10%     
MSM, FSW, STI 
pts., blood donors, 
refugees, prisoners, 
workers, military 
personnel, truck 
drivers, migrants 
15  1997  1,575  0.0%    Fes 
15  1997  1,085  0.09%    Tangier 
15  1997  1869  0.11%    Rabat 
15  1997  1,568  0.13%    Tetouan 
15  1997  722  0.14%    Casablanca 
15  1997  722  0.14%    Oujda 
15  1997  292  0.34%    Marrakech 
15  1997  246  0.41%    Agadir 
FSWs: Female sex workers, MSM: Men who have sex with men, STD: Sexually transmitted disease, STIs: Sexually transmitted infections, TB: 
Tuberculosis, VCT: Voluntary HIV counseling and testing 
a Point–prevalence surveys on different population groups as extracted from UNAIDS epidemiological facts sheets on Morocco over the years.
34 
Some of the data reported here are gleaned from country-based case notification surveillance reports,
20 or provided through national-level 
agencies. These surveys may not be conducted using sound methodology or internationally accepted guidelines for HIV surveillance. There are 
also very limited information on the populations on which these measurements were made. Given these limitations, the prevalence levels may not 
be representative of the populations that they are supposed to represent.  
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2.7.2  Analysis of HIV/AIDS notified cases 
 
2.7.2.1 Overall patterns of notified HIV/AIDS cases  
 
Between 1986 and 2009 a total of 4,972 cases of HIV/AIDS were notified, of which 31.8% were 
asymptomatic HIV cases. Table 9 displays the total number of notified HIV/AIDS cases in 
Morocco by period, indicating the percentage of HIV cases among new diagnoses in each period.  
 
Table 9. Distribution of notified HIV/AIDS cases by period, 1986-2009.
17 
Period  HIV 
cases 
AIDS 
cases  Unknown  Total period  HIV/ 
total period 
Total period/ 
total cumulative 
1986-1989  30  44    74  40,5%  1,6% 
1990-1994  169  205    374  45,0%  7,5% 
1995-1999  117  473    590  19,8%  11,9% 
2000-2004  384  867    1251  30,6%  25,1% 
2005-2009  845  1714  124  2683  33,0%  53,9% 
Total cumulative  1,545  3,303  124  4,972  31,8%  100% 
 
It is worth noting that the percentage of females among the total notified HIV/AIDS cases 
increased steadily from 19.3% in 1986-1989 to 47.9% in 2005-2009.
17 Furthermore, the burden 
of HIV cases appears to be shifting from males to females, with 61.6% of total HIV cases in 
2005-2009 being females.
17 Also, 73% of women affected with HIV/AIDS during the period 
2005-9 were unemployed as compared to 31.7% of males. Overall, age groups 25-34 years and 
35-44 years accounted for 38.4 and 32.1% of the total HIV cases in that same period.
17 
 
Table 10 displays the distribution of notified HIV/AIDS cases by region for the period 2005-
2009. It indicates that for that period, Sous Massa Draa accounted for about 25% of the total 
notified cases, followed by Marakesh Tensift Al Haouz (21.3%) and Grand Casablanca 
(12.4%).
17 
 
Table 10. Distribution of HIV/AIDS notified cases by region, 2005-2009.
17 
Region  HIV 
cases 
AIDS 
cases  Total region  Total region/ 
total cumulative 
Souss Massa Draa  227  411  638  24,9% 
Marrakech Tensift Al Haouz  162  384  546  21,3% 
Grand Casablanca  165  154  319  12,4% 
Doukkala Abda  39  154  193  7,5% 
Tanger Tétouan  22  116  138  5,3% 
Rabat Salé Zemmour Zaer  37  93  130  5,1% 
Guelmim Es Semara  30  67  97  3,8% 
Oriental  15  76  91  3,5% 
Meknes Tafilalet  24  48  72  2,8% 
Laâyoune Boujdour Sakia El Hamra  16  50  66  2,6% 
Fés Boulemane  21  31  52  2,0% 
Chaouia Ouardigha  27  24  51  2,0% 
Tadla Azilal  9  21  30  1,2% 
Taza Al Hoceima Taounate  8  15  23  0,8% 23 
 
Table 10 continued. Distribution of HIV/AIDS notified cases by region, 2005-2009.
17 
Region  HIV 
cases 
AIDS 
cases  Total region  Total region/ 
total cumulative 
Gharb Chrarda Beni Hsen  4  12  16  0,6% 
Oued Ed Dahab Lagouira  2  8  10  0,4% 
Other   37  50   107   4,1% 
Total  845  1,714  2,559  100% 
 
 
2.7.2.2 Risk factors among notified HIV/AIDS cases 
 
Table 11 shows the distribution of HIV/AIDS notified cases in Morocco by risk factor. Multiple 
partnership and affected spouse constitute the main risk factors accounting for 74 and 15% of 
cases, respectively.
17 
 
Table 11. Distribution of notified HIV/AIDS cases by risk factor, 2005-9.
17 
  Females N (%)  Males N (%)  Total N (%) 
Multiple partners  732 (63%)   1,171 (82%)     1,903 (74%) 
Affected spouse  295 (25%)             87 (6%)     382 (15%) 
Drug use  14 (1%)             69 (5%)      83 (3%) 
Affected mother  23 (2%)             36 (3%)            59 (2%) 
Transfusion  11 (1%)             16 (1%)            27 (1%) 
Other  93 (8%)            45 (3%)          138 (5%) 
Total         1.168 (100%)         1,424 (100%)        2,592 (100%) 
 
 
2.7.3  Modes of transmission among reported HIV cases 
 
2.7.3.1 Distribution of HIV cases by mode of transmission  
 
As can be seen from several studies and sources displayed in Table 12, heterosexual transmission 
is the predominant mode of transmission of HIV cases in Morocco. Figure 2 displays the mode 
of transmission by year as extracted from the Ministry of Health national HIV database.
16  
 
Table 12.  HIV modes of transmission for Morocco. 
Mode of Transmission  Point of Prevalence 
Heterosexual transmission  72%,
45 77%,
45 80%,
48 83%,
50 80%
16 (total 1986-2009) 
Homosexual transmission  4%,
48 7%,
45 4%
16 (total 1986-2009) 
Injecting drug transmission  4%,
48 11%,
45 3%
16 (total 1986-2009) 
Blood or blood products transmission  0.62%,
45 1%,
48 1%
16 (total 1986-2009) 
Mother to child transmission  3%,
48 4.63%,
45 1% 
16 (total 1986-2009) 
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Figure 2. Mode of HIV transmission in Morocco by year, 1986-2009. 
 
 
 
 
2.7.3.2 Parenteral HIV transmissions other than injecting drug use  
 
Parenteral transmission of HIV other than IDU has been documented in Morocco and HIV 
prevalence has been measured among a number of populations at risk of parenteral HIV 
acquisition. Occupational injuries among health care workers are common in Morocco where 
they were found to be at high frequency, though rarely declared.
51-52 Around 59% of health care 
workers in Morocco report a needle stick injury in the previous year.
53 Table 13 lists HIV 
prevalence for populations exposed to parental transmissions other than IDU.  
 
Table 13. HIV prevalence for populations at risk of parental transmissions other than IDU in 
Morocco.  
Population   Source  Year   Sample size  Prev.  HIV-1  Prev.  HIV-2  Comment 
Chronic renal 
failure victims 
15  1984-7  47  0.0%    Casablanca 
Hemodialysis 
Patients 
15  1999  615  0.0%    Casablanca 
 
15  1997  615  0.0%     
 
54      0%     
Hemophiliacs 
15  1993?  40  0.0%  0.0%  Casablanca.  
 
15  1997?  99  0.0%     
 
15  1999?  99  0.0%    Casablanca 
Polytranflused 
patients 
15  1984-7  474  0.21%    Casablanca 
 
15  1991?  171  0.0%  0.0%  Rabat. Children 
 
 
2.7.3.3 Hepatitis C Virus as proxy for HIV parenteral transmission  
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Hepatitis C Virus (HCV) prevalence is a powerful proxy of the potential spread of HIV through 
the parenteral modes of transmission in different populations,
55-57 and the most prevalent 
transfusion-transmitted infection.
58 Table 14 summarizes HCV point-prevalence among different 
population groups in Morocco. HCV incidence among haemodialysis patients in Morocco was 
very high at 9.41% per person-year.
59 Persons in certain professional categories might be at 
higher risk of being infected, or transmitting the infection, due to exposures to bodily fluids such 
as barbers who appear to have about five-fold higher HCV prevalence than the general 
population, at 5% in Morocco.
37 Studies among traditional barbers in Morocco have shown that 
the risk of blood-borne infectious diseases was not known to barbers nor to their customers and 
that hygiene conditions were deficient.
37, 60  
 
Table 14. HCV prevalence in different population groups in Morocco. 
Population Group  Prevalence Rate 
Blood donors  1.1%
61 
Pregnant women  1.0%
61  
ANC attendees and family planning clinic  0.5%
20 
Barbers, all men  5.0%
37 
Haemodialysis patients  35.1%,
61 68.3%,
5976%,
54  
Hemophiliac patients   42.4%
61 
ANC: Antenatal clinics  
 
2.7.4  Proxy Biological Markers of Sexual Risk Behavior 
 
HPV, Herpes simplex virus type 2 (HSV-2), and bacterial STIs can be used as proxies of the 
levels of sexual risk behavior in the population and its manifestation in terms of exposure risk to 
HIV.
62-63 Table 15 illustrates STI prevalence among different population groups in Morocco.  
 
Table 15. STI prevalence for different population groups in Morocco. 
STI  Population  Source  Prevalence  
HPV  Controls, hospital-based case-control study 
14  21.0% 
HSV-2       
  General population:      
  Men 
20  10.0% 
  Women 
20  13.0% 
  Urban women with a median age of 40 years 
64  26.0% 
  ANC attendees 
65  12.9% 
   
36  12.7% 
  Family planning center attendees  
36  18.3% 
  Facility based population:     
  STD clinic attendees 
20  6.7% 
  Male HIV sentinel surveillance attendees 
65  9.2% 
   
20  16.2% 
  Potential bridging population:     
  Military personnel 
65  6.5% 
Syphilis       
  General population: 
20  2.8% 
  Blood donors  
66  1.3% 
  Hotel staff 
21  0.4% 26 
 
Table 15 continued. STI prevalence in percent for different population groups in Morocco. 
STI  Population  Source  Prevalence  
   
33  0.94% 
  Male laborers 
21  0.0% 
   
33  4.51% 
  Seasonal female laborers  
33  2.17% 
   
21  2.9% 
  Symptomatic primary healthcare center attendees 
46  5.6% 
  ANC attendees 
36  1.6% 
  Pregnant women  
33  0.73% 
   
21  1.0% 
   
66  3.0% 
  Family planning center attendees  
46  3.4% 
   
36  3.5% 
  Facility based population:     
  TB patients 
21  2.3% 
   
33  4.0% 
  STD clinic attendees 
21  3.8% 
   
20  4.0% 
   
33  4.92% 
   
49  13.2% 
   
46  18.4% 
  Females STD clinic attendees 
20  2.7% 
   
19  2.4% 
  Vulnerable population:     
  Male prisoners 
21   4.03% 
   
21  4.8% 
  Female prisoners 
21  7.8% 
   
33  16.39% 
   
42  23% 
  Female prisoners imprisoned for sex work  
21  9.6% 
   
33  11.76% 
  Potential bridging population:     
  Sailors  
21  1.9% 
   
33  3.37% 
  Truck drivers 
21  9.55% 
  Key population at risk:     
  FSWs  
21  9.0% 
   
21  12.1% 
   
33  13.29% 
   
20  17.0% 
   
19  13.8% 
Gonorrhea       
  General population:     
  ANC attendees 
36  0.7% 
  Family planning center attendees  
46  3.2% 
   
36  1.0 
  Symptomatic primary healthcare center attendees 
46  5.4% 
  Facility based population:     
  STD clinic attendees 
46  10.0% 
   
20  42% 
   
67  52.4% 
  Male STD clinic attendees  
49  7.07% 
  Female STD clinic attendees 
20  0.8% 
   
49  1.74% 27 
 
Table 15 continued. STI prevalence in percent for different population groups in Morocco. 
STI  Population  Source  Prevalence  
   
19  1.0% 
  Key populations at risk:     
  FSWs  
20  3.5% 
   
19  7.1% 
Chlamydia       
  General population:     
  ANC attendees 
36  2.7% 
  Family planning center attendees 
46  2.6% 
   
36  5.2% 
  Symptomatic primary healthcare center attendees 
46  6.3% 
  Facility based population:     
  STD clinic attendees 
46  5.0% 
   
20  6.0% 
   
67  17.1% 
   
49  51.5% 
  Female STD clinic attendees 
19  5.6% 
  Key populations at risk:     
  FSWs  
19  19.1% 
ANC: Antenatal clinics, FSWs: Female sex workers, HPV: Human Papilloma Virus, HSV-2: Herpes simplex virus type 2, STD: 
Sexually transmitted disease, TB: Tuberculosis, STI: Sexually transmitted infection 
   
Cervical cancer is the second most common cancer in Morocco,
14 accounting for 14.7% of 
cancer cases in the country. The age-standardized rate of cervical cancer incidence is 13.2 per 
100,000 women and the mortality rate is 10.7 per 100,000 women per year.
68 Though HSV-2 
prevalence among the general population is rather low in comparison to many settings around the 
world, it is relatively high compared to other MENA countries ranging between 10-26%.
20 
Figure 3 shows the age stratified prevalence of HSV-2 among general population men and 
women in a study from Morocco.
65 The prevalence grows rather slowly for both males and 
females as opposed to other regions,
65, 69 suggesting that it takes a long time after sexual debut 
for the risk of exposure to this sexually transmitted infection to be appreciable in magnitude. An 
alternative explanation might be a changing experience of successive birth cohorts in being 
exposed to HSV-2 infection in different eras.
70 However this explanation seems unlikely as 
recent trends suggest increasing, rather than declining, sexual risk behaviors.  
 
Bacterial STIs are mainly prevalent among populations with high risk practices, or their partners, 
and are not common among general population groups.
71 Their prevalence levels are specifically 
indicative of the presence of substantial risk behaviors in a small part of the population, as 
opposed to HPV and HSV-2 infections which may propagate in populations at intermediate or 
even relatively low risk behaviors. Different studies have documented bacterial STI prevalence 
in different population groups in Morocco. Between 180,000 and 240,000 new STDs used to be 
reported annually in the late 1990s in Morocco,
49 but in recent years the number of reported 
cases increased considerably (370,000 in 2005).
50 Figure 4 shows the trend in STI notified cases 
in Morocco from 1992 to 2006. 
 
 28 
 
Figure 3. HSV-2 prevalence for selected populations by age group in Morocco.
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Figure 4. Trend in STI notified cases in Morocco, 1992–2006. 
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2.7.5  HIV Molecular Epidemiology 
 
Molecular epidemiology could be valuable in tracking the evolution of the epidemic among 
different risk groups, understanding sexual and injecting risk networks of MARPs, and 
identifying transmission pathways among the populations in a given country.
72-74  In Morocco, 
subtype B was historically found to be the dominant strain, accounting for 93.5% of infections in 
the nineties and reflecting transmission pathways of West European origins.
75 However, more 
recent data indicate that although subtype B remains the predominant strain, there is an 
increasing diversity of HIV-1 variants with over 25% of the infections being of non-B subtypes, 29 
 
including several circulating recombinant forms (CRFs), and reflecting sub-Saharan immigration 
to Europe via Morocco or possibly acquisitions by Moroccans traveling in sub-Saharan Africa.
76  
   
2.8  HIV/AIDS knowledge and attitudes 
 
Table 17 summarizes the level of HIV/AIDS knowledge and the nature of attitudes towards 
PLHIV in different population groups in Morocco.      
 
Table 17. Levels of HIV/AIDS knowledge and attitudes towards PLHIV among different 
population groups in Morocco 
Levels of Knowledge  Population groups 
High basic knowledge  General population women, 
77-78 blood donors,
79 youth (national),
80 youth,
24 
IDUs,
23 FSWs,
18 truck drivers
25 
Low comprehensive knowledge  Youth (national),
80 IDUs
23 
Comprehensive HIV/AIDS 
knowledge 
Youth,
24 FSWs
18 
High levels of misinformation  General population women,
77 youth,
24 FSWs,
18 truck drivers
25 
Positive attitudes towards people 
living with HIV/AIDS 
Youth (national),
80 Youth,
24 
Negative attitudes towards 
people living with HIV/AIDS 
Youth (national),
80 Youth,
24 truck drivers
25 
FSWs: Female sex workers, IDUs: Injecting drug users 
 
2.9  Condom use 
 
The prevalence of condom use in Morocco showed variability according to the population group. 
Table 18 summarizes patterns of condom use by different population groups in Morocco as 
extracted from available studies and reports. 
 
Table 18. Condom use among different population groups in Morocco. 
Population   Prevalence of condom use 
General population women:  16% (ever use)
14 
Incarcerated women:  9% (regular use)
42 
Mainly IDUs: 
 
Overall: 
23 
Consistent: 5.9% (males), 19.5% (females)  
Often: 5.5% (males), 3.9% (females)  
Rarely: 25.8% (males), 15.6% (females)  
Never: 29.2% (males), 36.4% (females)  
 
Last 12 months: 
23 
Consistent: 11.7% (males), 20.8% (females)  
Sometimes: 25.1% (males), 19.5% (females) 
Never: 58.8% (males), 53.2% (females)  
FSWs: 
 
Last 30 days with clients:
18 
 
Consistent: 59.5% (vaginal sex), 26.1% (anal sex), 16.9% (oral),  
Almost always: 9.8% (vaginal sex), 10.9% (anal sex), 10.8% (oral), 
Sometimes: 21.7% (vaginal sex), 13.0% (anal sex), 14.9% (oral), 
Never: 9.0% (vaginal sex), 50.0% (anal sex), 57.4% (oral),  
 
Last sex with non-paying partner: 35.6%
18 30 
 
 
Table 18 continued. Condom use among different population groups in Morocco. 
Population   Prevalence of condom use 
Youth: 
 
Last sex with a FSW: 65.3% 
 
Last sex: 71% (males), 62.5% (females), 70.4% (total) 
 
Average number of condoms used in the last month:  
1.5 (males), 2.0 (females), 1.5 (total) 
Truck drivers  Last sex:
25 
Overall: 29% 
Commercial: 36.7% 
Casual heterosexual: 36.3% 
 
Last 12 months with FSW:
25 
Consistent: 24% 
Almost always: 6% 
Sometimes: 13% 
Never: 54% 
 
Last 12 months with casual partner:
25 
Consistent: 27% 
Almost always: 7% 
Sometimes: 19% 
Never: 44% 
FSWs: Female sex workers, IDUs: Injecting drug users 
 
In one study, the main reason for non-condom use by FSWs was reported to be objection of the 
client (40% of  FSWs).
18 Non-availability of condoms was the reason for only 9% of FSWs. 
Encouragingly, 46.3% of FSWs said that they would refuse to have sex in case no condom was 
available.
18 
 
Condom use as a contraception method among the general population: 
 
In the 2003-4 DHS survey in Morocco, 11.4% of married women ever used a condom for 
contraception, while 1.5% were currently using them as a contraception method.
44 In an earlier 
study conducted in 1999, 1.3% of antenatal clinics (ANC) attendees and 8.2% of women seeking 
family planning services ever used condoms for contraception.
3631 
 
CHAPTER III. MoT MODEL PARAMETERS, ASSUMPTIONS, AND JUSTIFICATION 
 
The main sources of data that were used to estimate the parameter inputs in the MoT model are: 
1)  The Morocco HIV/AIDS Synthesis Review detailed in Chapter II. Specific studies or 
corresponding tables from the Review are mentioned as references in the parameters Tables 
19-23 below.  
2)  The synthesis review of HIV epidemiology in other MENA countries as extracted from the 
MENA HIV/AIDS Synthesis Project.
1 This source of data is referred to in the parameters 
tables as ‘SMENA: Studies in other MENA countries’ 
3)  Global HIV data, referred to as ‘GA: Global analyses’ 
4)  Consensus agreement following discussions among national experts and stakeholders and 
the research team during the national MoT workshop that was held in Morocco in the 
preparatory phases of the MoT exercise, referred to as ‘CA’. 
 
Tables 19-23 below describe the different parameters used in the MoT model, their values, the 
justification and/or calculations behind their choice, and the source of data used for their 
estimation. In many cases, the final parameter used was a representative or reasonable value 
based on a combination of the above data sources. 
 
3.1  Biological parameters 
 
Table 19 summarizes the biological parameters that were used in the MoT model including the 
transmission probabilities per type of exposure and the effect of male circumcision on HIV 
transmission probability. It bears notice that we have incorporated the effect of STIs on HIV 
transmission probability per coital act directly and hence the effect of STIs as a biological 
cofactor on transmission probability was not included explicitly in the model structure. This 
choice reflects the findings of a state of art systematic review and meta-analysis of HIV 
transmission probability per coital act.
81-82    
 32 
 
Table 19. Biological HIV transmission parameters of the MoT model. 
Parameter   Value  Justification  Reference 
Transmission probability per HIV 
exposure from needle sharing 
0.008  Systematic review and meta-analysis of HIV transmission 
probability per coital act in observational studies 
82-83 
Transmission probability per non-
commercial vaginal sex act 
0.0034  Systematic review and meta-analysis of HIV transmission 
probability per coital act in observational studies 
81-82 
Transmission probability per 
commercial vaginal sex act 
0.0051  Systematic review and meta-analysis of HIV transmission 
probability per coital act in observational studies 
81-82 
Transmission probability per anal 
sex act 
0.01  Systematic review and meta-analysis of HIV transmission 
probability per coital act in observational studies 
81-82, 84 
Reduction in female to male 
transmission probability per 
vaginal sex act due to male 
circumcision 
60%  Finding of three clinical trials 
85-87 
Prevalence of male circumcision  99%  More than 99% of the population of Morocco practice 
male circumcision as a religious obligation and based on 
CA  
 
Transmission probability per HIV 
exposure from medical injections 
0.004  Systematic review and meta-analysis of HIV transmission 
probability per injection in observational studies 
82-83 
Transmission probability per HIV 
exposure from blood transfusions 
0.925  Systematic review and meta-analysis of HIV transmission 
probability per transfusion in observational studies 
82-83 
 
 
3.2  Risk group size estimates 
Table 21 summarizes the risk group size estimates, in terms of numbers and prevalence of risk, 
of the different population groups defined in Table 1. The risk group size estimates were 
calculated using the Morocco demographic attributes, in terms of population size and overall 
HIV prevalence, as defined in Table 20. 
 
Table 20. Demographic attributes for Morocco. 
Parameter   Value  Reference 
Total population size in Morocco (TP)  29,891,708 
88 
Total 15-49 yrs adult population size (TAP)  17,829,000 
89 
Male (TMP)  8,914,500 
89 
Female (TFP)  8,914,500 
89 
Adult (15-49 yrs) HIV prevalence  0.11% 
10, 90 33 
 
Table 21. Risk group size estimate for each HIV risk group in the Morocco MoT model. 
Population   Prevalence of risk  Risk group size estimate 
  Total (TAP)  Male (TMP)  Female (TFP)  Total (TAP)  Male (TMP)  Female (TFP) 
IDUs  0.1%  0.19%  0.02%  18,500  16,576  1,924 
Calculation  # IDUs/ TAP  (total # IDUs x (1-
fraction of IDUs who 
are female))/ TMP 
(# IDUs x fraction of 
IDUs who are 
female)/ TFP 
   Total # IDUs x (1- 
fraction of IDUs who 
are female)  
Total # IDUs x 
fraction of IDUs who 
are female  
Justification &/or 
reference 
UNODC data
29  Fraction of IDUs who 
are female: 10.4%
23  
Fraction of IDUs who 
are female: 10.4%
23  
UNODC data
29  Fraction of IDUs who 
are female: 10.4%
23  
UNODC data
29 
Stable sexual 
partners of IDUs 
0.05%  0.01%  0.09%  9,250  962  8,288 
Calculation  (Fraction of the TMP 
who are stable sexual 
partners of IDUs + 
Fraction of the TFP 
who are stable sexual 
partners of IDUs) /2 
Prevalence of IDU 
among females x 
fraction of IDUs who 
are in a stable sexual 
partnership 
Prevalence of IDU 
among males x 
fraction of IDUs who 
are in a stable sexual 
partnership 
# of males in a stable 
sexual partnership 
with IDUs + # of 
female in a stable 
sexual partnership 
with IDUs 
# of female IDUs x 
fraction of IDUs who 
are in a stable sexual 
partnership 
# of male IDUs x 
fraction of IDUs who 
are in a stable sexual 
partnership 
Justification &/or 
reference  
  50% of IDUs are in a 
stable sexual 
partnership: RV based 
on SMENA,
1 on CA, 
and on GA 
50% of IDUs are in a 
stable sexual 
partnership: RV based 
on SMENA,
1 on CA, 
and on GA 
  50% of IDUs are in a 
stable sexual 
partnership: RV based 
on SMENA,
1 on CA, 
and on GA 
50% of IDUs are in a 
stable sexual 
partnership: RV based 
on SMENA,
1 on CA, 
and on GA 
FSWs  0.375%  --  0.75%  66,859  --  66,859 
Calculation  Half the prevalence of 
sex work among 
females  
    Prevalence of sex 
work among females 
x TFP 
  Prevalence of sex 
work among females 
x TFP 
Justification &/or 
reference  
    Based on one study 
among hospital 
attendees,
14 in the 
intermediate to high 
range for available 
data in SMENA,
1 and 
based on CA 
     
Clients of FSWs  3.75%  7.5%  --  668,588  668,588  -- 
Calculation  Half of the fraction of 
males seeking FSWs 
    Fraction of males 
seeking FSWs x TMP 
Fraction of males 
seeking FSWs x TMP 
 
Justification &/or 
reference  
  Based on CA         34 
 
Table 21 continued. Risk group size estimate for each HIV risk group in the Morocco MoT model. 
Population   Prevalence of risk  Risk group size estimate 
  Total (TAP)  Male (TMP)  Female (TFP)  Total (TAP)  Male (TMP)  Female (TFP) 
Stable sexual 
partners of FSWs 
clients 
1.96%  --  3.92%  349,671  --  349,671 
Calculation  Half the fraction 
among females  
  Fraction of TFP who 
are married x fraction 
of the TMP seeking 
FSWs  
Fraction of the TFP 
who are partners of 
FSWs clients x TFP 
  Fraction of the TFP 
who are partners of 
FSWs clients x TFP 
Justification &/or 
reference  
    52.3% of women are 
married in Morocco
44 
     
 MSM  0.25%  0.5%  --  44,573  44,573  -- 
Calculation  Half the prevalence of 
MSM among males 
    Prevalence of MSM 
among males x TMP  
Prevalence of MSM 
among males x TMP 
 
Justification &/or 
reference  
  RsV based on 3.7% of 
sexually active youth 
ever having anal sex 
with males,
24 and 
based on SMENA
1 
and on CA.  
       
Stable female 
partners of MSM 
0.05%  --  0.1%  8,915  8,915   
Calculation  Half the fraction of 
women who are 
partners of MSM 
    Fraction of females 
who are partners of 
MSM x TFP 
Fraction of females 
who are partners of 
MSM x TFP  
 
Justification &/or 
reference  
    20% of MSM have 
female partners (RV 
based on SMENA
1 
and on CA) and 0.5% 
of males are MSM  
     
People engaged in 
casual HS 
5.75%  10%  1.5%  1,025,168  891,450  133,718 
Calculation  (Prevalence of casual 
HS among males + 
prevalence of casual 
HS among females) /2  
  
    # of males engaged in 
casual HS + # of 
females engaged in 
casual HS  
Prevalence of casual 
HS among males x 
TMP  
Prevalence of casual 
HS among females x 
TFP  
 35 
 
Table 21 continued. Risk group size estimate for each HIV risk group in the Morocco MoT model. 
Population   Prevalence of risk  Risk group size estimate 
  Total (TAP)  Male (TMP)  Female (TFP)  Total (TAP)  Male (TMP)  Female (TFP) 
Justification &/or 
reference  
  RsV based on the 
measures of sexual 
behavior among the 
general population 
and on CA 
15% of the prevalence 
of casual HS among 
males, based on the 
study among youth 
where 36% of males 
and 5.2% of females 
declared having ever 
had vaginal sex
24 
     
Stable partners of 
people engaged in 
casual HS 
2.54%  0.075%  5%  452,411  6,686  445,725 
Calculation  (Fraction of males 
who are partners of 
casual HS people + 
Fraction of females 
who are partners of 
casual HS people) / 2 
Fraction of females 
engaged in casual HS 
x fraction of them 
having steady/spousal 
partners 
 
Fraction of males 
engaged in casual HS 
x fraction of them 
having steady/spousal 
partners 
 
  Fraction of males who 
are stable partners of 
people engaged in 
casual HS x TMP  
Fraction of females 
who are partners of 
people engaged in 
casual HS x TFP  
Justification &/or 
reference  
  Assuming a RsV of 
5% of females 
engaged in casual HS 
having steady/spousal 
partners and based on 
CA 
Assuming a RsV of 
50% of males 
engaged in casual HS 
having steady/spousal 
partners and based on 
CA 
     
People with no risk 
HS this year 
27.5%  20%   35%   4,902,975  1,782,900  3,120,075 
Calculation  (Prevalence of no risk 
HS in males + 
prevalence of no risk 
HS among females) /2 
    # of males with no 
risk HS + # females 
with no risk HS 
Fraction of the TMP 
with no risk HS x 
TMP 
Fraction of the TFP 
with no risk HS x 
TFP 
Justification &/or 
reference  
  CA and RsV based on 
levels of reported 
sexual activity among 
youth and marriage 
rates in Morocco 
24 
CA and RsV based on 
levels of reported 
sexual activity among 
youth and marriage 
rates in Morocco 
24 
     
People with low 
risk HS 
57.67%  61.73%  53.61%  10,282,092  5,502,766  4,779,326 36 
 
Table 21 continued. Risk group size estimate for each HIV risk group in the Morocco MoT model. 
Population   Prevalence of risk  Risk group size estimate 
  Total (TAP)  Male (TMP)  Female (TFP)  Total (TAP)  Male (TMP)  Female (TFP) 
Calculation        # of males engaged in 
low risk HS + # of 
females engaged in 
low risk HS 
Prevalence of low risk 
HS among males x 
TMP  
Prevalence of low risk 
HS among females x 
TFP  
Justification &/or 
reference  
Those who are not in 
any of the previous 
risk group categories 
nor their sexual 
partners/clients 
Those who are not in 
any of the previous 
risk group categories 
nor their sexual 
partners/clients 
Those who are not in 
any of the previous 
risk group categories 
nor their sexual 
partners/clients 
     
Population at risk 
of medical 
injections  
100%  100%  100%  17,829,000  8,914,500  8,914,500 
Justification &/or 
reference  
Assuming all the 
adult population is at 
risk  
Assuming all the 
adult population is at 
risk  
Assuming all the 
adult population is at 
risk  
Assuming all the 
adult population is at 
risk  
Assuming all the 
adult population is at 
risk  
Assuming all the 
adult population is at 
risk  
Population at risk 
of blood 
transfusions 
0.2%  0.2%  0.2%  35,658  17,829  17,829 
Calculation  (# of blood donations 
per year / # of 
transfusions per 
person)/ TP 
(# of blood donations 
per year / # of 
transfusions per 
person)/ TP 
(# of blood donations 
per year / # of 
transfusions per 
person)/ TP 
# of blood donations 
per year /# of 
transfusions per 
person 
(# of blood donations 
per year /# of 
transfusions per 
person)/2 
(# of blood donations 
per year /# of 
transfusions per 
person)/2 
Justification &/or 
reference  
203,000 blood 
donations per year
30 
Average of 3 transf. 
per person  
203,000 blood 
donations per year
30 
Average of 3 transf. 
per person  
203,000 blood 
donations per year
30 
Average of 3 transf. 
per person  
     
CA: Consensus agreement in the national MoT workshop, FSWs: Female sex workers, HS: Heterosexual sex, GA: Global analyses, IDUs: Injecting drug users, MSM: Men who 
have sex with men, RV: Representative value, RsV: Reasonable value, TAP: Total adult population (15-49 yrs), TFP: Total adult female population (15-49 yrs), TMP: Total 
adult male population (15-49 yrs), SMENA: Studies in other Middle East and North Africa countries, UNODC: United Nations Office on Drugs and Crime  37 
 
3.3  HIV prevalence  
 
Table 22 shows the estimated HIV prevalence among the different population groups defined in 
Table 1.  
 
Table 22. HIV prevalence for each HIV risk group in the Morocco MoT model. 
Population   Value  Justification  Reference 
IDUs  2%   Representative value based on available point 
prevalence measures and on CA 
Table 2 
Stable sexual partners of IDUs  1%   Half of the HIV prevalence among IDUs based on 
CA 
 
FSWs  2%   Representative value based on available point 
prevalence measures and on CA 
Table 2 
Clients of FSWs  0.5%   Representative value based on available point 
prevalence measures among STD clinic attendees 
and on CA 
Table 8 
Stable partners of clients of 
FSWs 
0.25%   Half of the HIV prevalence among clients based on 
CA 
 
MSM  2%   Representative value based on available point 
prevalence measures and on CA 
Table 2 
Females partners of MSM  1%  Half of the HIV prevalence among MSM   
People engaged in casual HS  0.22%    Twice the prevalence of HIV in the adult population 
in Morocco and based on available prevalence 
measures among different general population 
groups and on CA 
Table 6 
Stable partners of people 
engaged in casual HS 
0.11%   Half of the HIV prevalence among people engaged 
in casual HS 
 
People engaged in low risk HS  0.082%   Average of HIV prevalence among ANC attendees 
and blood donors, and based on CA. 
Table 6 
People with no risk HS this year  0.03%  The value needed to achieve a 0.1% prevalence 
among the total population 
 
Blood transfusions  0.032%  HIV prevalence among blood donors  
30 
 ANC: Antenatal clinics, FSWs: Female sex workers, CA: Consensus agreement, HS: Heterosexual sex, IDUs: Injecting drug 
users, MSM: Men who have sex with men, STD: Sexually transmitted disease 
 
 
3.4  Risk behavior parameters 
 
Table 23 summarizes the estimated risk behavior parameters including number of partnerships, 
number of acts of exposure, and percentage of acts of exposure that are protected among the 
different population groups defined in Table 1.   38 
 
Table 23. Risk behavior parameters for each HIV risk group in the Morocco MoT model.  
Risk behavior   Value  Justification  Reference 
Partnerships, Number per year of:       
IDU partners per IDU  3  CA and representative value based on SMENA and on GA   
Clients/partners per FSW  100   CA and representative value based SMENA and on the following 
specific data from Morocco: In one study, slightly over 50% of 
FSWs had one client during the last working day, 18% had two 
clients and 33.3% had less than one client. The average number 
of clients during the last 7 days was 4.3 clients. In another study, 
70% of the respondents had more than 4 clients per week. 
18-19 
FSW partners per client  4   CA and in order to balance the number of acts between FSWs 
and clients 
 
MSM partners per MSM   5  CA and representative value based on SMENA. Also, truck 
drivers in Morocco reported an average of 5 same-sex partners 
during the last year  
25 
 
Partners per person engaged in casual HS  2   Based on CA   
Rate of medical injections per person per year  4.3  Average value for the MENA region  91 
Number of acts of exposure per year among:       
IDUs (# of shared injections per IDU per year)  50  Representative value based on GA and on CA    
Stable heterosexual sex partners of IDUs (# sex 
acts per stable partner of IDU per year) 
50  Representative value based on GA and on CA. Also, over 80% of 
women seeking antenatal or family planning services had sexual 
relations at least once per week.  
36 
FSWs (# of sex acts per partner/client per FSW per 
year) 
4  Representative value based on a total number of coital acts of 
400 per year or about 1 act per day with a total of 100 partners 
per year and CA 
 
Clients of FSWs (# of sex acts per FSW per 
partner/client per year) 
10  Based on CA    
Stable heterosexual sex partners of clients of 
FSWs (# of sex acts with stable partner per client 
of FSW per year) 
50  Representative value based on GA and on CA. Also, over 80% of 
women seeking antenatal or family planning services had sexual 
relations at least once per week.  
36 
MSM (# of anal sex acts per MSM partner per 
year) 
15  Based on a total number of coital acts of 75 distributed over an 
average of 5 partners per year and CA 
 
Stable female heterosexual sex partners of MSM 
(# of sex acts between the MSM and his stable 
female partner per year) 
50  Representative value based on GA and on CA. Also, over 80% of 
women seeking antenatal or family planning services had sexual 
relations at least once per week.  
36 
People engaged in casual HS (# of casual sex acts 
per person engaged in casual HS) 
20  Based on CA   39 
 
Table 23 continued. Risk behavior parameters for each HIV risk group in the Morocco MoT model.  
Risk behavior   Value  Justification  Reference 
Stable heterosexual sex partners of people engaged 
in casual HS (# of sex acts between people 
engaged in casual HS and their stable partner) 
50  Representative value based on GA and on CA. Also, over 80% of 
women seeking antenatal or family planning services had sexual 
relations at least once per week.  
36 
People engaged in low risk HS (# of sex acts per 
person) 
50  Representative value based on GA and on CA    
Percentage of acts protected        
1) Sharing of needles/equipment among IDUs  50%  Based on the prevalence of 63.9% of ever sharing syringes and  
representative value based on SMENA and on GA 
1, 23 
2) Condom use among:       
IDUs and their stable heterosexual sex partners  2%    Based on the following DHS data: 11.4% of married women ever 
used a condom for contraception, while 1.5% were currently 
using them as a contraceptive method and on CA. 
44 
FSWs and their clients/partners  25%  Based on the frequency of condom use in different population 
groups in Morocco and CA 
Table 18 
Clients of FSWs and their stable heterosexual sex 
partners 
2%    Based on the following DHS data: 11.4% of married women ever 
used a condom for contraception, while 1.5% were currently 
using them as a contraceptive method and based on CA. 
44 
MSM  25%  based on the frequency of condom use in different population 
groups in Morocco and on CA 
Table 18 
MSM and their female heterosexual sex partners  2%    Based on the following DHS data: 11.4% of married women ever 
used a condom for contraception, while 1.5% were currently 
using them as a contraceptive method and CA. 
44 
People engaged in casual HS  25%  Based on the frequency of condom use in different population 
groups in Morocco and on CA 
Table 18 
People engaged in casual HS and their 
steady/spousal heterosexual sex partners 
2%    Based on the following DHS data: 11.4% of married women ever 
used a condom for contraception, while 1.5% were currently 
using them as a contraceptive method and CA. 
44 
People engaged in low risk HS  2%    Based on the following DHS data: 11.4% of married women ever 
used a condom for contraception, while 1.5% were currently 
using them as a contraceptive method and CA. 
44 
Percentage of medical injections that are sterile 
and non-shared 
99%  Based on CA   
Percentage of blood transfusions that are screened 
for HIV 
99%  Based on Blood Bank data and on CA 
90 
CA: Consensus agreement, DHS: Demographic and Health Survey, FSWs: Female sex workers, GA: Global analyses, HS: Heterosexual sex, IDUs: Injecting drug users, MSM: 
Men who have sex with men, SMENA: Studies in other Middle East and North Africa countries, STI: Sexually Transmitted Infections 40 
 
CHAPTER IV. LIMITATIONS AND GAPS IN MoT MODEL AND DATA 
 
4.1  Limitations of MoT model structure 
 
The MoT model simplifies several aspects of the reality of HIV transmission in order to yield 
broad conclusions within a reasonable time frame. Some of the model’s predictions may not be 
satisfactorily precise. Nevertheless, the MoT model process is essential in the formulation of 
public health policy in relation to HIV as it focuses decision making on the key issues to be 
explored, identifies the gaps in our knowledge of the epidemic, and allows policy makers and 
stakeholders to explore the implications and ramifications of certain widely-held assumptions 
about the nature of the epidemic within the borders of their country. The MoT model process 
itself should be seen as a goal as well as a deliverable of this project, in addition to the findings 
of the model. It is basically an exercise in building capacity for quantitatively-oriented and 
evidence-based rational decision making process.     
 
One of the key limitations of the MoT model is that it does not incorporate overlapping risk 
factors though a considerable fraction of persons engaged in MARNs may have more than one 
risk behavior practice exposing them to HIV infection. Another limitation is that the model 
calculates HIV incidence over the short-term of only one year. The model cannot capture 
adequately the secondary HIV transmission effects arising from the onward transmission and 
percolation of HIV infection in the population. To address this limitation, the MoT model 
process needs to be repeated or updated annually or bi-annually by incorporating new data and 
understanding their implications in terms of HIV transmission.     
 
Another limitation of the model is that it assumes an average risk behavior rather than a 
distribution of risk behavior within each risk group. The model also does not capture in its 
structure existing correlations in the epidemic process, such as that between the status of an 
individual and his/her partner or HIV prevalence and gender. There is also no distinction in the 
model between serial or concurrent partnerships. Another shortcoming is that the model 
estimates HIV incidence that arises only within the borders of the country and does not account 
for exogenous HIV exposures which tend to contribute considerable fraction of HIV incidence in 
the MENA region.
1 It appears however from discussions with our national partners that the vast 
majority of incident HIV infections arise from transmissions within Morocco. Indeed, less than 
2% of HIV notified cases identified in Morocco are among Moroccans living outside of Morocco 
or having lived outside Morocco.
92 
    
Finally, a key limitation of this model, in relation to Morocco specifically, is that it is applied at 
the national level rather than at a local or regional level. The model is not optimized to address 
the heterogeneity of HIV transmission in this country. In future versions of the model, provided 41 
 
there will be wealth of data available at the local or regional levels, efforts should explore the 
possibility of expanding the application of the model to the provincial or city levels.   
 
4.2  Gaps in available scientific evidence 
 
Though Morocco is one of the leading two countries in MENA in terms of availability of HIV-
related scientific evidence, key strategic scientific data are either lacking or of limited quality or 
representativeness, thereby hindering our ability to reach adequately precise predictions. Nearly 
all model parameters have not yet been established with a high or even satisfactory degree of 
rigor. The following parameters for each risk group need to be well-established in order to have a 
better quantification of disease frequency measures in the population: 
1)  IDUs: precise estimation of the size of the IDU population, HIV prevalence, frequency of 
sharing injections, frequency of injecting drug use, number of partners sharing with, 
number of acts of sharing per partner, percentage of sharing acts that are protected, 
fraction of IDUs engaged in stable heterosexual sex partnerships, frequency of coital acts 
within this sexual partnership, and frequency of condom use within this partnership.  
2)  FSWs: precise estimation of the fraction of women who exchanged sex for money, gifts 
or other commodities within the last 12 months; HIV prevalence; number of clients per 
day, week, month, and year; frequency of coital acts per commercial sex partner; and 
frequency of condom use with commercial sex partners. 
3)  Clients of FSWs: precise estimation of the fraction of men who exchange money, gifts or 
other commodities for sex within the last 12 months; HIV prevalence; number of 
commercial heterosexual sex partners within the last 12 months; frequency of coital acts 
per commercial heterosexual partner; frequency of condom use in commercial 
heterosexual sex partnerships; fraction of clients of FSWs engaged in stable heterosexual 
sex partnerships; frequency of coital acts within this stable sexual partnership; and 
frequency of condom use within this stable sexual partnership. 
4)  MSM: precise estimation of the fraction of males who had anal sex with males within the 
last 12 months, HIV prevalence, number of anal sex partners within the last 12 months, 
frequency of coital acts per anal sex partner, frequency of condom use with anal sex 
partners, fraction of MSM engaged in stable heterosexual sex partnerships with females, 
frequency of coital acts within this stable sexual partnership, and frequency of condom 
use within this stable sexual partnership. 
5)  Casual heterosexual sex networks: precise estimation of the fraction of men and women 
who engaged in casual heterosexual sex within the last 12 months, HIV prevalence, 
number of casual heterosexual sex partners within the last 12 months, frequency of coital 
acts per casual heterosexual sex partner, frequency of condom use with casual 
heterosexual sex partner, fraction of population engaged in casual heterosexual sex that 
are engaged also in stable heterosexual sex partnerships, frequency of coital acts within 42 
 
this stable sexual partnership, and frequency of condom use within this stable sexual 
partnership. 
6)  Low-risk population: precise estimation of the fraction of men and women who are 
engaged only in stable monogamous heterosexual sex partnerships within the last 12 
months, HIV prevalence, frequency of coital acts, and frequency of condom use. 
7)  No risk population: precise estimation of the fraction of men and women who were not 
engaged in any sexual partnership within the last 12 months. 
8)  Medical injections: precise estimation of the number of medical injections per person per 
year in Morocco, and fraction of medical injections that are sterile and non-shared.  
9)  Blood transfusions: precise estimation of the number of blood transfusions per person per 
year in Morocco, and fraction of transfusions that are fully screened for HIV. 
 
These gaps in our knowledge are best addressed through mapping and risk group size estimations 
of key populations at risk, integrated bio-behavioral surveillance surveys on these populations, 
and population-based sexual behavior survey on a nationally representative sample.  
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CHAPTER V. RESULTS OF THE MoT MODEL 
 
Using the MoT model and the model input parameters specified above, we obtained estimates for 
the sizes of various risk groups and different epidemiologic measures that relate to HIV 
transmission in Morocco. In addition to the risk group size estimates found in Table 21, Table 24 
lists the key predictions of the MoT model for Morocco in terms of estimated number of PLHIV 
and HIV incidence among the different population groups defined in Table 1. Further key 
findings of the MoT model are found in Table 25.  
 
As can be seen in Table 21, commercial heterosexual sex networks are the largest of the three 
kinds of MARNs comprising an estimated 66,859 FSWs and 668,588 clients. MSM networks 
come second comprising 44,573 persons, while IDUs form the smallest MARP consisting of 
18,500 persons. Nearly five percent of the Moroccan sexually active population (8.2% of males 
and 0.8% of females) engage in at least one MARN (Table 25). Moreover, 10.2% of the 
population (18.2% of males and 2.3% of females) engage at any given year in intermediate to 
high risk networks, that is IDUs, MSM, FSWs and clients, and people engaging in casual 
heterosexual sex. 
 
There are an estimated 367,836 (2.1% of the population) spouses or regular partners 
(predominantly women) who may be vulnerable to HIV infection as their sexual partners engage 
in risk behavior in MARNs (Table 25). Additionally, there are an estimated 452,411 spouses or 
regular partners (2.5% of the population) who may be vulnerable, though at substantially reduced 
risk, because their partners are engaged in casual heterosexual sex (Table 21). It is estimated that 
70.7% of all HIV infections among women are due to an infected spouse (Table 25), and that 
slightly more than half (52.4%) of HIV incidence is among females (Table 24). Meanwhile, 
89.1% of new HIV infections among men are due to engagement in MARNs (Table 25).  
HIV incidence (the number of HIV infections per year), and incidence rate (the number of HIV 
infections per person-year) vary substantially among the different risk groups in the population.  
 
As can be seen in Table 24, the highest incidence rate is predicted to be among IDUs at 1.07% 
per person-year, followed by MSM at 1.04%, and then by FSWs at 0.74%. Though HIV 
incidence rate is very small in the low-risk population at only 0.01% per person-year, the actual 
number of new infections is largest at 906 HIV cases per year simply because this risk group 
comprises most of the sexually active population in Morocco. These incidence rate measures 
suggest that HIV prevalence seems likely to increase in the future and may reach levels as high 
as 11.3% among IDUs, 11.1% among MSM, and 8.2% among FSWs (Table 24). However, HIV 
prevalence in the whole sexually active population is likely to remain low and probably will 
never reach a value close to 1%.   
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Table 24. Key predictions of the MoT model for Morocco.  
Population   Estimated # 
of PLHIV 
HIV 
Incidence  
Percentage 
of incidence 
Incidence 
among males 
Incidence 
among females 
Incidence of 
females / total 
HIV incidence 
(/ person-year) 
Equilibrium 
Prevalence 
IDUs  370  197  5.7%  177  21  10.4%  1.07%  11.34% 
  Sexual partners of IDUs  93  28  0.8%  3  25  89.6%  0.31%  3.54% 
FSWs  1,337  497  14.4%  0  497  100.0%  0.74%  8.19% 
   Clients  3,343  821  23.8%  821  0  0.0%  0.12%  1.45% 
   Partners of Clients  874  268  7.8%  0  268  100.0%  0.08%  0.91% 
MSM  891  465  13.5%  465  0  0.0%  1.04%  11.13% 
   Female partners of MSM  89  27  0.8%  0  27  100.0%  0.30%  3.52% 
Casual heterosexual sex  2,255  82  2.4%  72  11  13.0%  0.01%  0.10% 
   Partners of casual HS  498  152  4.4%  2  149  98.5%  0.03%  0.40% 
Low-risk heterosexual   8,431  906  26.3%  101  805  88.9%  0.01%  0.11% 
No risk   1,430     0.0%                
Medical injections     3  0.1%  2  2  50.0%  0.00%  0.00% 
Blood transfusions     0  0.0%  0  0  50.0%  0.00%  0.01% 
Total adult population  19,612  3,446  100.0%  1,641  1,805  52.4%  0.02%  0.23% 
FSWs: Female sex workers, HS: Heterosexual sex, IDUs: Injecting drug users, MSM: Men who have sex with men, PLHIV: People living with HIV 45 
 
Table 25. Key results of analyses on the findings of the MoT model for Morocco. 
Finding  Proportion 
Infections originating from:   
Commercial sex networks (lower bound)  46.0% 
MSM networks  14.3% 
Injecting drug networks  6.5% 
Three most at risk networks (CS,MSM,IDUs) (lower bound)  66.8% 
Casual heterosexual sex networks  6.8% 
Discordant partnerships in the low-risk general population  26.3% 
Parenteral transmissions other than IDU  0.1% 
Infections among:   
Women due to risk factor of infected spouse  70.7% 
Men due to engagement in most at risk networks   89.1% 
Partners of high-risk individuals  13.8% 
Population in most at risk networks:   
Males  8.2% 
Females  0.8% 
Population  4.5% 
Fraction of males among people at high risk  91.4% 
Fraction of females among people at high risk  8.6% 
Population in intermediate to high risk networks:   
Males  18.2% 
Females  2.3% 
Population  10.2% 
Fraction of males among people at intermediate to high risk  88.9% 
Fraction of females among people at intermediate to high risk  11.1% 
Partners of members of most at risk networks:   
Number  367,836 
Fraction of population   2.1% 
Partners of members of high- and intermediate-risk networks    
Number  820,247 
Fraction of population  4.6% 
CS: Commercial sex, IDUs: Injecting drug users, MSM: Men who have sex with men 
 
 
The distribution of new HIV infections by mode of exposure can be seen in Table 24 and is 
schematized in Figure 5 and Figure 6 which also includes the uncertainty around the model 
predictions. The largest share of HIV incidence in any one risk group (26.3%) occurs among the 
low-risk heterosexual population, followed by clients of FSWs (23.8%), and FSWs (14.4%). 
MARNs predominantly drive the HIV epidemic and contribute a total of at least 66.8% of HIV 
infections. Commercial heterosexual sex networks contribute 46.0% of HIV incident infections 
followed by MSM networks (14.3%) and IDU networks (6.5%). The remaining one-third of HIV 
incidence in Morocco is distributed among the rest of the population groups including people 
engaged in casual heterosexual sex (6.8%) and the low-risk population (26.3%). Very small HIV 
incidence is predicted to be arising from medical injections or blood transfusions (0.1%) (Table 
24 and Figures 5 & 6). 
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Figure 5. Distribution of new HIV infections by mode of exposure as predicted by the MoT 
model for Morocco. 
 
 
 
Figure 6. Distribution of new HIV infections by mode of exposure including the uncertainty in 
the MoT model predictions for Morocco.  
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CHAPTER VI. DISCUSSION AND CONCLUSION 
 
6.1  Discussion of the Morocco HIV/AIDS Synthesis Review findings 
   
In summary, the data reviewed as part of the Morocco HIV/AIDS Synthesis Review indicates 
that there is no evidence for an HIV epidemic in the general population of Morocco. All data 
suggest that the general population is not, and unlikely will be in the foreseeable future, a major 
driver of HIV dynamics. However, similar to what is observed in MENA countries, a trend of 
rising epidemics among MARPs, such as commercial sex networks, seems to be emerging if not 
establishing itself in Morocco, though at relatively low prevalence. HIV prevalence among 
potentially bridging populations appears to be limited and parenteral transmission from medical 
injections and blood products seems very confined in this country.  
 
Although data about IDUs and MSM are limited and decisive conclusions about the status of the 
HIV epidemic among these two MARPs cannot be reached with the current level of evidence, 
the scattered data suggest that the epidemic among IDUs and MSM has a highly heterogeneous 
geographic distribution in Morocco. There appears to be localized endemic HIV transmission in 
certain settings such as among IDUs in Nador, Northern Morocco, and among MSM in 
Marrakesh and Agadir, Southern Morocco, while HIV transmission in other localities still 
appears to be limited.  
 
However, the available limited data on these two populations suggest high risk behavior. IDUs in 
Morocco reported high levels of sharing of injecting equipment, were mostly sexually active, and 
reported high levels of sexual risk behavior including multiple partners and overlapping sexual 
risk behavior with MSM and commercial heterosexual sex networks. Levels of comprehensive 
HIV knowledge among IDUs in Morocco tended to be low despite high levels of basic HIV 
knowledge, and condom use was very limited. The prevalence of IDUs in Morocco still appears 
to be lower than the prevalence of IDUs in the Eastern part of MENA (Mashreq); however it is 
evident that there is real potential for substantial epidemic among this MARP in Morocco. Data 
about risk behavior among MSM are more limited. Still, same-sex anal sex was observed at 
relatively high levels among many population groups including IDUs, youth, and truck drivers 
who particularly reported high levels of risk behavior with an average number of 5 same-sex 
partners during the last year.
25 HIV prevalence among truck drivers and other potentially 
bridging populations still remains limited in Morocco.  
   
The prevalence of sex work among women in Morocco is in line with the range for MENA, 
though it appears to be on the higher end. Unlike the epidemic among IDUs and MSM, there is 
conclusive evidence for HIV transmission among FSWs in much of Morocco (at a national HIV 
prevalence less than 5%), and the HIV epidemic is concentrated in the Southern part of the 
country mainly in Agadir and Marrakesh where HIV prevalence exceeds 5%. FSWs in Morocco 48 
 
appear to engage in high risk behavior such as overlap with injecting risk networks (about 1% of 
FSWs in Morocco are IDUs)
18 and multiple partnerships of different kinds. The considerable 
levels of STI prevalence among FSWs further substantiate the considerable levels of sexual risk 
behavior. However, condom use at least among FSWs who access VCT services appears to be 
rather high relative to other MENA countries (about 60% of FSWs with access to VCT services 
used condoms consistently in the last month).
18 In fact, there appears to be also good coverage of 
VCT services among FSWs in the main cities as a consequence of the active engagement of 
NGOs in Morocco with this risk group. Levels of basic HIV knowledge appear to be high among 
FSWs in Morocco and some groups even had fairly comprehensive HIV knowledge despite 
common misconceptions.  
 
The analysis of the notified HIV/AIDS cases indicate that multiple heterosexual sex partnerships 
is the leading risk factor for HIV acquisition, further confirming the dominance of the 
heterosexual mode of HIV transmission in Morocco. These analyses also indicate a clear trend 
whereby the burden of HIV cases appears to be shifting from males to females. Despite recent 
increases in the fraction of asymptomatic HIV cases diagnosed compared to earlier years thanks 
to the expansion in VCT programs, case notifications show that most cases are being diagnosed 
at later stages, suggesting still low coverage of HIV testing in Morocco.  
 
 
6.2  Discussion of the MoT model findings 
 
The sizes of the MARNs in Morocco relative to the adult population, as estimated from the MoT 
model, are somewhat comparable to those in other MENA countries. The prevalence of IDU in 
Morocco is about half of the average prevalence of IDU in MENA,
1 and substantially lower than 
the average prevalence globally.
22, 29, 93 The prevalence of sex work among women is in the 
intermediate to the high range compared to other MENA countries,
1 but substantially lower than 
that in other regions.
94 Similarly, the prevalence of male same-sex anal sex appears to be 
comparable to other MENA countries,
1, 95 but on the low side compared to other regions.
96-100 
 
Almost 5% of the Moroccan adult population are at elevated risk of HIV infection, being IDUs, 
MSM, FSWs or clients of FSWs, compared to the rest of the population. In addition, about 10% 
of the population appear to engage in casual heterosexual sex putting them at rather an 
intermediate risk of HIV infection. Almost 90% of the population that engage in intermediate to 
high risk networks are males. 
 
The core driver of the HIV epidemic in Morocco are MARNs including commercial heterosexual 
sex networks, MSM networks, and IDU networks, contributing two-third of total HIV incidence. 
HIV incidence among commercial heterosexual sex networks continues to be the leading driver 
of HIV incidence in Morocco and alone contributes about half of new HIV infections every year. 49 
 
MSM and IDUs networks contribute combined just over 20% of HIV incidence every year. 
Despite the relatively large number of people engaged in casual heterosexual sex, the 
contribution of this mode of exposure to total HIV incidence is quite small at about 7%. 
 
Though the low-risk population contributes 26.3% of new HIV infections, these HIV 
transmissions are occurring among stable discordant partnerships where the HIV infected index 
person is transmitting the infection to his/her spouse. While these infections are occurring in a 
currently low-risk population, they are HIV transmissions from index partners who likely 
acquired the infection in the past through engagement in MARNs. Therefore, and as suggested 
by other epidemiological evidence, it is unlikely that there will be a substantial HIV epidemic 
among the general population in Morocco.  
 
There are several reasons that may explain the rather low incidence of HIV in Morocco 
compared to other settings. These include, among others, the nature of sexual networks in this 
country in consideration of the prevailing socio-cultural norms,
1 as well as the prevention efforts 
developed by Morocco. One other key reason is male circumcision with its 60% efficacy against 
HIV acquisition based on the findings of three randomized clinical trials.
85-87 Using the MoT 
model, we estimated that male circumcision has prevented directly 32.4% of the HIV incidence 
that would have occurred if there was no male circumcision coverage in the population 
(calculation not included in this report). The risk group that benefited the most from male 
circumcision is clients of FSWs, where current HIV incidence is only 41% of the incidence that 
would have occurred if male circumcision was not practiced in Morocco. Male circumcision has 
substantially reduced the intensity of HIV transmission in commercial heterosexual sex networks 
in this country and is likely one of the key reasons behind the relatively low intensity HIV 
transmission in these networks despite the prevailing high risk behaviors. The male-only 
protective effect of male circumcision is also one of the key reasons for the fact that HIV 
incidence among women is about equal to that of men even though about 90% of high risk 
behaviors in Morocco are practiced by men.     
 
The MoT model predictions show that men and women contribute nearly equally to HIV 
incidence in agreement with the distribution among notified cases (Table 11). However, the key 
risk factor for HIV infection among men is engagement in MARNs (almost 90%) while the 
leading risk factor for HIV infection among women is an infected spouse. About 70% of women 
are predicted to acquire HIV infection from their regular sexual partners highlighting the 
vulnerability of women in discordant partnerships. This pattern is also seen in the rest of the 
MENA region where the vast majority of HIV infections among women are due to acquisitions 
from an infected spouse.
1 
 
It must be noted here that this prediction of the MoT model appears to contradict the distribution 
by risk factor of notified HIV/AIDS cases (Table 11). Among notified cases, 63% of women 50 
 
report multiple sexual partners as the risk factor versus only 25% report acquiring the infection 
from an infected husband. This paradox may simply reflect the highly heterogeneous coverage of 
HIV testing and VCT services in Morocco. Apart from blood donors and military recruits, there 
is virtually no mandatory or routine HIV testing in Morocco. VCT coverage continues to be 
limited for all risk groups with the exception of FSWs where several NGOs are active in 
providing VCT services to this risk group throughout much of the main cities. By far, FSWs are 
the leading beneficiary of VCT services in Morocco (about 25% of VCT attendees are FSWs)
1 
and this is probably the reason for a higher diagnosis rate among them. Meanwhile, women who 
acquire the infection from their spouses are rarely tested and are identified to be HIV positive 
only when advanced HIV and AIDS symptoms start appearing. 
 
Parenteral HIV transmissions other than IDU in Morocco, such as through medical injections or 
blood transfusions, are predicted to be rare thanks to universal blood screening and adequate 
precautions in the use of medical injections. The rather low HCV prevalence in the general 
population (Table 14) also suggests that this mode of transmission is unlikely to be a concern for 
HIV transmission in Morocco.  
 
Given the uncertainties around the majority of the model parameters, we cannot make conclusive 
statements on the size of the HIV epidemic in Morocco. The relative contribution to incidence of 
each MARN compared to the other ones is also not certain. This is due to the fact that Morocco 
does not yet have representative and comprehensive data about two key groups at high risk of 
infection: IDUs and MSM. It is hoped that this situation will improve markedly within the next 
two years with the implementation of several integrated bio-behavioral surveillance surveys 
(IBBSS) among IDUs and MSM, in addition to FSWs. These surveys will incorporate state of 
the art sampling methodologies for hidden and hard-to-reach populations such as respondent 
driven sampling (RDS).     
 
The uncertainty analysis conducted on our model predictions suggests that there are considerable 
uncertainties in the quantitative predictions of our model. The limitations in our knowledge of 
the model parameters, due to lack of data or limited quality or representativeness of studies, 
hinders our ability to make quantitatively concrete estimates. However, the overall picture 
emerging from our analysis, that is of MARN driving the HIV epidemic in Morocco, is likely to 
be robust against these uncertainties, especially that the epidemiological evidence delineated in 
the Morocco HIV/AIDS Synthesis Review is in the same line and substantiate the findings of the 
MoT model. 
 
Our model findings agree well with the findings of the SPECTRUM
10 and EPP
13 models for 
Morocco. Our predicted HIV incidence is nearly equal to that predicted by SPECTRUM and 
EPP (3447 in MoT versus 3268 in SPECTRUM and 3200 in EPP in 2010). However, we predict 51 
 
somewhat smaller number of PLHIV than estimated by SPECTRUM and EPP (19,612 in MoT 
versus 22,674 in SPECTRUM and 25,000 in EPP).  
 
6.3  Conclusion 
 
The nature of the HIV epidemic in Morocco appears to be rather similar to the nature of HIV 
epidemics in the rest of the MENA region.
10-11 HIV prevalence continues at low levels and HIV 
transmission is focused in MARNs including FSWs and their clients, MSM, and IDUs. While the 
evidence is still insufficient, there appears to be concentrated HIV epidemics among IDUs, 
MSM, and FSWs in at least parts of Morocco. The HIV epidemic in commercial heterosexual 
sex networks appears, though rather stable and not yet concentrated at the national level, to be 
more intense than in most other MENA countries.
1, 11   
 
It is often the case that IDU and MSM epidemics are more intense and lead to higher HIV 
prevalence than heterosexual commercial sex epidemics. In Morocco, where the opposite trend is 
currently observed from the available data, there is a possibility that there could be hidden HIV 
epidemics among IDUs and MSM that have not yet been captured by the surveillance 
infrastructure in this country, which is heavily focused on commercial heterosexual sex 
networks. The planned RDS studies in Morocco in the next two years should be able to shed 
light on this paradox of apparently low HIV transmission among IDUs and MSM, despite the 
existence of considerable endemic transmission among FSWs. 
 
It is plausible that over the next decade the HIV epidemic in Morocco will expand particularly 
among FSWs and their clients, MSM and IDUs. We may witness the rise of concentrated 
epidemics among some of these risk groups in some localities (prevalence > 5%). Nonetheless, it 
is unlikely that the HIV epidemic will make any major inroads into the general population. Most 
HIV infections in the low-risk population will continue predominantly to be linked to chains of 
transmission originating in the MARNs.  
 
In conclusion, Morocco has the most developed HIV/AIDS surveillance, research capacity, and 
response in the Arab World. Yet there are still severe gaps in the generation of representative 
HIV data. There are ample limitations in HIV prevalence measures, risk group size estimates, 
and sexual and injecting risk behavior measures. Strategic and robust data on the key populations 
at risk are still to a large extent missing.   52 
 
CHAPTER VII. RECOMMENDATIONS 
 
There are two sets of recommendations in relation to the HIV epidemic in Morocco. The first set 
is concerned with establishing strategic scientific evidence to understand the gaps in our 
knowledge of the HIV epidemic in this country. The second set of recommendations is 
concerned with implications of the MoT project findings in relation to HIV response and 
programming. 
 
7.1  HIV strategic information 
 
The key gap in strategic information in Morocco is the gap in our understanding of HIV 
prevalence, risk group size estimates, and risk behavior measures among IDUs, MSM, and FSWs 
and their clients. There is immediate need to conduct representative and multi-center IBBSS 
studies among these populations incorporating state of the art sampling methodologies for hidden 
and hard-to-reach populations such as RDS. These studies must be repeated at least every 2 to 3 
years to yield longitudinal data that will help us track the temporal trend of the epidemic in the 
different risk groups. It is essential for these studies to include not only HIV serological 
measures, but also other biomarkers of risk behavior such as HCV, HSV-2, and other bacterial 
STIs. 
 
The second priority for HIV scientific research in Morocco is mapping and scientific risk group 
size estimation of IDUs, MSM, and FSWs and their clients. Mapping and size estimation is 
essential for the quantitative assessment of HIV epidemiology and trends, and is integral to the 
process of planning targeted prevention strategies and programs. 
 
Morocco has the most developed sentinel surveillance system in the MENA region. 
Nevertheless, this system needs to be expanded particularly in relation to IDUs, MSM, and 
FSWs and their clients. The geographic coverage of the sentinel surveillance needs to be 
extended and the number of subjects surveyed need to be substantially increased to arrive at 
statistically meaningful prevalence measures.  
 
Our knowledge of sexual behavior in the general population in Morocco continues to be very 
limited. It is essential to conduct a population-based sexual behavior survey on a nationally 
representative sample to understand sexual partnership formation, nature of partnerships, 
prevalence of casual heterosexual sex, prevalence of sex work, prevalence of contacts with 
female sex workers, prevalence of IDU, prevalence of male to male sexual contacts, and coital 
frequency within different kinds of partnerships.  
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7.2  HIV response & programming 
 
HIV response and programming in Morocco need to focus on the key groups at risk of HIV 
infection: FSWs and their clients, MSM, and IDUs. HIV testing and treatment must be very 
aggressively expanded among these population groups. Rapid expansion of harm reduction 
programs is key in areas where IDU is an important mode of transmission such as in Northern 
Morocco. Expansion of outreach and prevention programs among MSM is urgently needed just 
as for FSWs and their clients. Expansion of HIV awareness programs among women and men 
about condom use and improving women’s negotiations skills in relation to condom use is 
beneficial. Condom use awareness programs should not only focus on HIV, but also stress the 
use of condoms as an STI (other than HIV) prevention method. Expansion of use of female 
condoms among FSWs should be explored. Still, enhancing and introduction of new programs 
on the key populations at risk should not be at the expense of other programs on other relevant 
populations such as youth.  
 
The evidence gathered in this report indicates that Morocco does not have a single epidemic, but 
rather highly heterogeneous HIV transmission both geographically and by risk group. Therefore, 
the HIV response must be tailored to the nature of HIV transmission across the different parts of 
the country. HIV among IDUs is a problem in Northern Morocco while the most intense HIV 
spread among FSWs and their clients occurs in Southern Morocco. The HIV response must be 
prioritized for the risk groups and geographic settings where HIV is already endemic.   54 
 
 
 
KEY MESSAGES 
 
1)  Risk behavior networks involving FSWs and their clients, MSM, and IDUs 
predominantly drive HIV transmission in Morocco. These are the populations for which 
HIV response and programming efforts must be prioritized.  
 
2)  HIV transmission among most at risk networks shows a highly heterogeneous 
geographical distribution which should be addressed in intervention efforts at the national 
level. 
 
3)  Most high-risk behaviors are practiced by men. Though about half of incident HIV 
infections are among women, the majority of women acquire their infection from their 
infected spouses. 
 
4)  There is very limited HIV transmission in the general population in Morocco. Most HIV 
transmissions in the general population are linked directly to transmissions originating in 
most at risk networks.  
 
5)  HIV counseling, testing, and treatment coverage among the key populations at risk is far 
below what is needed. HIV counseling, testing, and treatment coverage must be 
aggressively expanded among these population groups. 
 
6)  There are still large gaps in our knowledge of the HIV epidemic in Morocco. Public 
health surveillance and scientific research efforts must be enhanced in line with the data 
gaps identified in this analysis. HIV public health policy must be an evidenced-based, or 
at least evidence-informed, policy.   
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APPENDIX I. STRUCTURE OF MoT MODEL EQUATIONS
1 
   
For a risk group exposed to HIV through sexual intercourse with partners, the number of new 
infections is estimated by 
 
         1 1 1 1 1
N
A A
S P P T T                    
 
 
where 
S   =   Number of susceptible individuals (uninfected individuals) 
N   =   Number of sexual partners per individual 
P   =   Prevalence of HIV in partners 
A   =   Number of unprotected acts with each partner 
  =   (Number of acts)  (Proportion of acts which are unprotected) 
β   =   Prevalence of sexually transmitted infections (STIs) 
T   =   Probability of transmission per contact with an HIV-infected partner in the  
    absence of STIs 
T  =   Probability of transmission per contact with an HIV infected partner in the 
presence of STIs 
  =   T (The relative increase in transmission probability from the presence of STIs) 
 
Analogous equations are derived for the non-sexual exposure to HIV. For injecting drug users, 
recipients of medical injections, and recipients of blood transfusions, exposure to HIV occurs 
through needle-sharing, receiving medical injections, and receiving blood transfusions, 
respectively. Acts are protected by the use of clean needles, safe medical injections, and safe 
screened blood, respectively.
                                                             
1 Reproduced with permission from ‘The modes of transmission of HIV in Africa Report, 2009’ 61 
 
APPENDIX II. SPREADSHEET OF THE MoT MODEL WITH RESULTS 
 
 
Country: Morocco Blue cells: Input necessary Transmission per act
Adult (15-49) population size: 17,829,000 Peach cells: Input optional Male -> female 0.0034      
Adult (15-49) HIV prevalence (%): 0.11% Orange cells: Output Female -> male 0.0014      
Estimated number of PLHIV 19612 Green cells: Need to check data % men circumcised 99.0%
STD cofactor 0
Adult Risk Behaviour Male Female Male Female
Total 
number 
with risk 
behaviour
Prevalence 
of HIV (%)
Number 
HIV+
Prevalence 
of STI (%)
Number of 
partners 
per year
Number of 
acts of 
exposure 
per partner 
per year
Percentage 
of acts 
protected 
(%)
 with STI No STI Incidence
% of 
incidence
Incidence 
per 100,000
Injecting Drug Use (IDU) 0.19% 0.02% 18,500 2.00% 370                 0.0% 3 50 50% NA 0.008 197 5.72 1,066
   Partners IDU 0.01% 0.09% 9,250 1.00% 93                   NA 1 50 2% -              0.0034       28 0.82 306
Sex workers 0.75% 66,859 2.00% 1,337             0.0% 100 4 25% -              0.0051       497 14.41 743
   Clients 7.50% 668,588 0.50% 3,343             0.0% 4 10 25% -              0.0021       821 23.81 123
   Partners of Clients 3.92% 349,671 0.25% 874                 NA 1 50 2% -              0.0034       268 7.78 77
MSM 0.50% 44,573 2.00% 891                 0.0% 5 15 25% -              0.0100       465 13.49 1,043
   Female partners of MSM 0.10% 8,915 1.00% 89                   NA 1 50 2% -              0.0034       27 0.79 304
Casual heterosexual sex 10.00% 1.50% 1,025,168 0.22% 2,255             0.0% 2 20 25% -              0.0016       82 2.39 8
   Partners CHS 0.08% 5.00% 452,411 0.11% 498                 NA 1 50 2% -              0.0034       152 4.40 34
Low-risk heterosexual  61.73% 53.61% 10,282,092 0.08% 8,431             0.0% 1 50 2% -              0.0023       906 26.29 9
No risk  20.00% 35.00% 4,902,975 0.03% 1,430             0.0% 0 0 0 0.00 0
Medical injections 17,829,000 0.11% NA 4 1 99% NA 0.004 3 0.10 0
Blood transfusions 0.20% 0.20% 35,658 0.03% NA 1 1 99% NA 0.925 0 0.01 1
TOTAL ADULT POPULATION 100% 100% 17,829,000 0.11% 19,612           Total incidence 3,447 19
Total incidence in partners of high-risk individuals 475 13.783 58
Use either method 1 or 2 to determine number with risk 
behaviour for each group (column F).
Transmission 
probability per risky 
exposure act
Method 2: Population 
with risk behaviour
Method 1: Percent of population 
with risk behaviour (%)
 